

Category of Companies

Pharmaceutical

- ABLBio, Inc
- ALTEOGEN Inc.
- AstraZeneca Korea
- BC WORLD PHARM. CO., LTD.
- Boryung pharmaceuticals Co., Ltd.
- Bukwang Pharmaceutical Co., Ltd.
- Celltrion, Inc.
- CHONG KUN DANG
- Corestem, Inc
- CrystalGenomics, Inc.
- DAEHWA Pharm
- Daewon Pharm. Co., Ltd.
- Daewoong Pharmaceutical Co., Ltd.
- GC Pharma(Former Green Cross Corp.)
- Genexine, Inc.
- HANDOK. Inc.
- HANLIM PHARM. CO., LTD.
- Hanmi Pharmaceutical Co., Ltd.
- Helixmith Co., Ltd.
- HK inno.N Corporation
- HUONS CO., LTD.
- HYUNDAI Pharm. Co., Ltd.
- Ildong Pharmaceutical Co., Ltd.
- ISU ABXIS CO., LTD.
- Janssen Korea
- JW Pharmaceutical
- KOLMAR KOREA
- Korea Otsuka Pharmaceutical Co., Ltd.
- Korea United Pharm, Inc.
- Kuhnii Pharmaceutical Co., Ltd
- LG Chem, Ltd
- Medytox Inc.
- Pharam Research Products
- Pharmicell Co., Ltd.
- Samjin Pharmaceutical Co., Ltd.
- Samyang Biopharmaceuticals Corporation
- SHIN POONG PHARM.CO.,LTD.
- SK Chemicals Co., Ltd.
- ST PHARM
- Taejoon Pharmaceutical Co., Ltd.
- TEGO SCIENCE
- Yuhan Corporation
- Yungjin Pharm. Co., Ltd.

Pharmaceutical

- AGERA BioTech, INC.
- AULBIO
- ELI Frontier Corporation
- Geneuin-Tech Co., Ltd.
- HEDGEHOG, Inc.
- Inventera Pharmaceutical Inc.
- KCNB Bio
- NANOFAENTECH
- NineBiopharm Co., Ltd.
- ONCOCROSS
- REACNF(Cellulose Nano Fibril)
- S&K Therapeutics
- TiCARos
- WellPep Co.,LTD

Medical Device

- Biot Korea Inc.
- ClariPi Inc.
- Gaia agricultural corporation Ltd.
- GH Innotek Co., Ltd
- Heimbiotek, Inc.
- INNOYARD LTD.
- INVITT.
- Kukdong R&D Center(3D Materials)
- MCK Tech. Co., Ltd.
- Medihub Co., Ltd.
- NeoDex Corp.
- ORGAMEDI co.ltd
- Remedia coporation
- Shinwoo medison
- TMD Lab Co., Ltd
- Well_C
- YBSOFT co., ltd.

Cosmetic

- Benacell Co., Ltd.
- Medicosbiotech.Inc

Health food products & IT

- Dadak company
- DELVER Incorporated
- SayM Co.,Ltd.
- Whatvita co.,Ltd.

Pharmaceutical



ABLBio, Inc.

CEO
Sang Hoon Lee

Location
2nd Floor, 16 Daewangpangyo-
Ro 712 Beon-Gil,, Bundang-Gu,
Seongnam-Si, Gyeonggi-Do,
13488, South Korea

Specialty
Immuno-oncology Therapeu-
tics, Multispecific Antibody,
BBB-penetrating Platform
Technology

Tel / Fax / E-mail
T. 82-31-8018-9800
F. 82-31-8018-9836
E. Info@ablbio.com

ABL Bio founded in 2016 is a fast growing biotechnology company developing novel innovative antibody therapeutics in the field of immuno-oncology and neurodegenerative diseases. ABL Bio develops more than 20 pipelines based on an unique bispecific antibody (BsAb) platform technology. ABL001 is the most advanced BsAb asset, targeting VEGF and DLL4, which is ongoing phase 1 clinical study. ABL Bio's BsAb platform technology enables to connect two different antibodies together, ensuing synergistic activity of the two antibodies. Grabody™ T belongs to a T cell engaging bispecific antibody and Grabody™ I is a dual immune modulating bispecific antibody for cancer treatment. Grabody™ B is a bispecific antibody using blood-brain barrier (BBB)-penetrating platform for neurodegenerative disease treatment.

Main Products



ABL001(NOV1501)

Product type	specific indication	Development Stage
ABL001(NOV1501)	a bispecific antibody therapeutics for malignant solid tumor	scheduled to conduct clinical trials of 1b/2

R&D Pipeline

		Indication	Early Discovery	Late Discovery	Pre-Clinical	Phase I	Phase II/ III
Angiogenesis	ABL001 (Anti-VEGF/DLL4 BsAb)	Solid Cancer					
Antibody-Drug Conjugate (ADC)	ABL20X	Cancer					
NexMab™ (ADC)	Grabody™ T(4-1BB) (Multiple Pipelines)	Cancer					 TAAx4-1BB BsAb
	Grabody™ I (PD-L1) ABL50X	Cancer					 PD-L1x4-1BB BsAb
	I/O mAb ABL40X	Cancer					 Novel I/O mAb
SC drug delivery	Grabody™ B ABL301 (α-Synuclein / IGF1R)	Parkinson's Disease					











ALTEOGEN Inc.

ALTEOGEN, located in Daejeon, South Korea, is a biotech venture company established in 2008. ALTEOGEN has developed proprietary NexP™, NexMab™ and Hybrozyme® platform technologies for long-acting biobetters, site-specific conjugated ADC and novel recombinant human hyaluronidase, respectively. ALTEOGEN aim to transform and improve care for the lives of those who are suffering from serious diseases, in search of therapies with our cutting-edge science and technology. ALTEOGEN was listed on KOSDAQ in 2014.

Main Products

Product type		Code name	indication	specific indication	Development Stage
Novel Biologics (Biobetter)	Recombinant fusion protein	ALT-P1	Growth hormone deficiency	Growth hormone deficiency	Phase 2
	Antibody drug conjugate	ALT-P7	Oncology	Breast cancer	Phase 1
	Recombinant protein	ALT-B4	Subcutaneous Absorption Accelerator	Oncology	Pre-clinical
Biosimilar		ALT-L9	Ophthalmic diseases	Wet Age Macular Degeneration	Phase 1
		ALT-LS2	Oncology	Breast cancer	Pre-clinical

R&D Pipeline

Technology	Pipeline	Research	Process Dev.	Pre-clinic	Phase 1	Phase 2	Phase 3
NexP™ (Biobetter)	Long-acting hGH, ALT-P1 (hGH deficiency)	 Adult Phase 2 in Korea					
		 Pediatric Phase 2 IND planned					
	Long-acting E1-FGF21, ALT-FL1 (NASH)		Co-development with Lynkogen				
NexMab™ (ADC)	Breast/Gastric cancers, ALT-P7	 Completed Phase 1 in Korea					
	Ovarian cancer, ALT-Q5						
Biosimilars	Herceptin® SC biosimilar, ALT-LS2 (Breast/Gastric cancer)						
	Eylea® biosimilar, ALT-L9 (wAMD)	 Phase 1 IND approved in Korea Global Phase 3 planned					
SC drug delivery	Novel Hyaluronidase (ALT-B4)						

CEO
Soon Jae Park, Ph.D.

Location
62, Yuseong-daero 1628beon-gil, Yuseong-gu, Daejeon, 34054, Korea

Specialty
1. NexMab™ Technology for site-specific ADC conjugation
2. NexP™ Technology for long-acting biobetter recombinant therapeutics
3. Hybrozyme™ Technology for the novel human recombinant Hyaluronidase

Tel / Fax / E-mail
T. 82-42-384-8780
F. 82-42-384-8770
E. info@alteogen.com



We push the boundaries of science to deliver life-changing medicines.

www.astrazeneca.com

AstraZeneca Korea

CEO
Juno Kim

Location
21F ASEM Tower, 517 Yeong-
dong-daero, Gangnam-gu,
Seoul, Korea

Specialty
Oncology, Cardiovascular,
Renal & Metabolism and
Respiratory

Tel / Fax / E-mail
T. 82-2-2188-0800
F. 82-2-2188-0852
E. webmaster.korea@astrazeneca.com

AstraZeneca Korea is a science-led biopharmaceutical business delivering life changing medicines to patients through innovative science and excellence in development and commercialization. It focuses on the development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory.

Main Products

Oncology



Cardiovascular and Metabolism

Respiratory

IRESSA (Non-small cell lung cancer)
TAGRISSO (Non-small cell lung cancer)
Imfinzi (Non-small cell lung cancer)
Lynparza (Ovarian Cancer)
Faslodex (Breast Cancer)

Forxiga (Type 2 diabetes)
Brilinta (Acute coronary syndrome)

Symbicort (Asthma, COPD)

R&D Pipeline

[illegible]

Partnered and/or in collaboration: 1 Registrational Phase II/III study

 Oncology Precision medicine approach under investigation

Phase I		Phase II		Phase III	
16 New Molecular Entities		22 New Molecular Entities		5 New Molecular Entities	
AZD0284 ROR γ agonist / respiratory	AZD8233 hypertension/cerebral cardiovascular	abeditera ¹⁸ LABA asthma / COPD	MED3506 Diabetic kidney disease	antrolumab ¹⁹ TULIP Type I IFN receptor SLE	
AZD0404-1 ²⁰ orexin 1 receptor antagonist opiod use disorder	AZD9977 MCR cardiovascular		MED3506 IL33 AD / COPD	ninsirovab ²¹ (MED8897) ²² RSV nAb-7YE passive RSV immunisation	
AZD0449 inhalated JAK inhibitor asthma	MED0618 PAR2 antagonist mAb-osteoarthritis pain	antrolumab ¹⁹ Type I IFN receptor lupus nephritis	MED3902 Pai/PoV Pseudomonas pneumonia	PT027 ICS/SABA asthma	
MED1626 inhalated IL4R α asthma	MED1341 ²³ alpha synuclein parkinson's/disease	AZD4831 MPO 1H β -eF	MED588 ²⁴ phosphodi modulation cardiovascular	roadact ²⁵ HFN1 anemias MDS	
AZD2693 nonalcoholic steatohepatitis	MED11614 ²⁶ amyloid β Alzheimer's disease	AZD5718 FLAP coronary artery disease	MED6012 LCAT cardiovascular	icecplumab ²⁷ NAVGTA TSP SOURCE TSLP severe uncontrolled asthma	
AZD56334 inhalated ENaC cystic fibrosis	MED05117H ²⁸ China IL8 7YE rheumatoid arthritis	AZD7594 inhalated SGRM asthma / COPD	MED7352 NG2/TNF- α OA pain / painful diabetic neuropathy		
AZD6615 hypertension/cerebral CV disease	MED0570 LOX-1 CV disease	AZD7968 ²⁹ DPPI1 COPD	roadact ²⁵ HFE-FH inhibitor chemo induced anemia		
AZD8154 inhalated PI3K δ cancer	MED17219 anti-diabetic type-2 diabetes	AZD8801 ³⁰ VEGF-A cardiovascular	sovalornab ³¹ o-Toxin Staphylococcus pneumonia		
		AZD8871 ³² MABA COPD	icecplumab ²⁷ TSLP atopic dermatitis		
		AZD9967 SGRM RA / respiratory	icecplumab ²⁷ TSLP COPD		
	conafide ³³ GLP-1/lipaguan type 2 diabetes / obesity (a.k.a. P-1)		estrupad ³⁴ URAT1 chronic kidney disease		

¹ includes novel combinations and additional indications for assets where the lead is not yet launched
[#] Partnered and/or in collaboration; [†] Registrational Phase II/III study **RinPharmaceuticals** **Precision medicine approach under investigation**



BC WORLD PHARM. CO., LTD.

BC World Pharm. Co., Ltd.(BCWP) has expertise in formulation and process development to provide quality generics. BCWP is not only certified as Korea Innovative pharmaceutical company, but also designated as Advanced Technology Center. In 2019, Carbapenem injections facility has been completed its construction in Wonju city. Starting with the commercialization of Carbapenem product, BCWP is preparing to enter global market such as US and Japan. Accordingly, the inspections for cGMP and PMDA are scheduled in this year.

Main Products



Meropenem 1g



Meropenem 500mg

Therapeutic class	Products	Remarks
Antibiotics (Carbapenem)	Meropenem Inj., Imipenem+Cilastatin Inj., Ertapenem Inj., Etc	Launched
Anti-Infectives	Vancomycin Inj., Metronidazole Gel., Etc.	Launched
Anti-TB	Rifampicin+Isoniazid+Pyrazinamide+Ethambutol Tab.	Launched
Anti-Hyperlipidemia	Atorvastatin Tab., Rosuvastatin Tab.	Launched
Anti-Hypertensive	Nicardipine HCl Inj., Amlodipine+Valsartan Tab., Etc	Launched
Gastrointestinal Agents	Rebamipide Tab., Etc	Launched
Narcotics	Fentanyl Sublingual Tab., Fentanyl Inj., Remifentanyl Inj., Morphine Inj., Etc.	Launched
Well-being Product	Glutathione Inj., Zinc sulfate hydrate Inj., Ascorbic Inj., Multipotent Inj. (Zn, Cu, Se, Cr, Mn, F, Fe, I, Mo), Etc.	Launched

R&D Pipeline

Category	Item	Indications	Stage
Injection	BCWP_D001	Anti-cancer	Pre-clinical
	BCWP_D003	Anti-cancer	Pre-clinical
	BCWP_D006	Anti-cancer	Pre-clinical
	BCWP_D007	Parkinson's disease	Pre-clinical
	BCWP_D008	Osteoarthritis pain of the knee	Formulation
	BCWP_D009	Anti-psychotic	Pre-clinical
	BCWP_D010	Anti-psychotic	Phase 1
	BCWP_D011	Anti-psychotic	Pre-clinical
	BCWP_D012	Anti-psychotic	Pre-clinical
Oral Dosage Form	BCWP_E008	Anti-Parkinson	Formulation
	BCWP_C003	Anti-hyperlipidemia	Phase 1
	BCWP_G1904	Antihistamine	Formulation
	BCWP_G1905	Antispasmodic	Formulation

CEO
Sung Han Hong

Location
Gyung Building, 78, 22-gil, Gaepo-ro, Gangnam-gu, Seoul, Republic of Korea

Specialty
1. Incrementally Modified Drugs
2. Drug Delivery System (DDS)
3. Generic

Tel / Fax / E-mail
T. 82-2-2181-0400
F. 82-2-574-5064
E. tree365@bcwp.co.kr



Boryung pharmaceuticals Co., Ltd.

www.boryung.co.kr/eng

CEO
Jae-hyun Ahn, Sam-soo Lee

Location
136, Changgyeonggung-ro,
Chongro-ku, Seoul

Specialty
1. Hypertension NCE
2. Oncology NCE
3. Cardiovascular disease IMD

Tel / Fax / E-mail
T. 82-2-708-8000
F. 82-31-491-5340

Boryung Pharmaceutical strives to be a company which will continue to practice 'contributing to the health of mankind' by preparing for the future and taking on challenges with innovation. We have made every effort to free everyone from the pains of disease. As a result, the people of Korea have come to love our products.

We has developed Kanarb, the No. 1 ARB in Korea, and kanarb combination drugs by our proprietary technology. We has successfully licensed out Kanarb Family to 38 countries.

Main Products

Product (Ingredient)	Use	Exporting Countries	Remarks
Kanarb (Fimasartan)	Hypertension	13 Latin countries, Russia, China, 13 Southeast Asian countries, 10 African countries	Launched
Dukarb (Fimasartan+Amlodipine)	Hypertension	25 Latin countries, 13 Southeast Asian countries, 10 African countries	Launched
Tuvero (Fimasartan+Rosuvastatin)	Essential hypertension and dyslipidemia	25 Latin countries, 13 Southeast Asian countries	Launched
Kanarb plus (Fimasartan+HTCZ)	Hypertension	13 Latin countries, 13 Southeast Asian countries, 8 African countries	Launched
Dukaro (Fimasartan+Amlodipine+Rosuvastatin)	Hypertension and dyslipidemia		Launched
Gelfos M (Colloidal Aluminum Phosphate, Magnesium hydroxide, Simethicone)	Gastric antacid	China, Taiwan	Launched
Besto (Lafutidine)	Gastric ulcer		Launched

R&D Pipeline

		Indication	Discovery	Preclinical	Phase I	Phase II	Phase III	Launch
NCE	BR2002	Lymphoma						
	BR2006	Cancer						
	BR2007	Cancer						
IMD	BR1006	Hypertension Dyslipidemia						
	BR1007	CKD						
	BR1008	Hypertension Dyslipidemia						
	BR1009	Hypertension Diabetes						
	BR1010	Hypertension						
	BR4002	Alzheimer's disease						



Bukwang Pharmaceutical Co., Ltd.

Bukwang, founded in 1960, is dedicated to bringing novel and outstanding medicines to the public.

As in-house developed products, Levovir® was developed as the 4th new drug in the world for hepatitis B and licensed out to Asia. Dexid® was developed for the treatment of diabetic neuropathy and is to be exported to East-Asia.

Bukwang has been actively investing in R&D, and continuing to pursue new drug development with various partners worldwide.

Main Products



Levovir®



Dexid®

Product (ingredient/formulation)	Indication	Exporting countries	Remarks
Levovir® capsule (Clevudine)	Chronic hepatitis B virus infection	Philippines	Launched
Dexid® tablet (R-thioctic acid tromethamine)	Diabetic polyneuropathy	East-Asian countries	Launched

CEO
Hee-Won Yoo

Location
7, Sangdo-ro, Dongjak-gu,
Seoul, Korea

Specialty
1. CNS Small molecules
2. Metabolic disorder Small molecules
3. Oncology Small molecules (including IMDs)

Tel / Fax / E-mail
T. 82-2-8288-114
F. 82-2-8288-029

R&D Pipeline

TA	Project	Indication	Category	Development phase				
				Discovery	Preclinical	Phase I	Phase II	Phase III
CNS	Lurasidone	Schizophrenia/ bipolar depression	Chemical					
Metabolism	MLR-1023	T2DM						
CNS	JM-010	Dyskinesia						
Oncology	SOL-804	Prostate cancer						
Immunology	BKC-1501A	Immune disorders						
Metabolism	BK-1701	Anti-diabetes/ Obesity						
CNS	USP8 Program	Neurodegeneration						
I-O	AhR inhibitor	Cancers						
CNS	PKR inhibitor	Neurodegeneration						



A global pharmaceutical company that promotes health and welfare for all



www.celltrion.com/en-us

Celltrion, Inc.

CEO
Kee Woo Sung

Location
23 Academy-ro, Yeonsu-gu,
Incheon Metropolitan City

Specialty
Biosimilars, New Drugs, Small
Molecules

Tel / Fax / E-mail
T. 82-32-850-5000
E. Contact@celltrion.com

Celltrion, Inc. is a leading Korean biopharmaceutical company that launched the world's very first antibody biosimilar product, Remsima®. As one of the first companies to chart the Korean biopharmaceutical sector, Celltrion pioneered many previously unexplored areas and evolved into one of the leaders in the biosimilar development and manufacturing sector with numerous milestone achievements. The company now plans to keep the momentum and continue the legacy as it ventures into new business areas such as small molecule pharmaceuticals and Ubiquitous-healthcare system with unique Celltrion approaches.

Main Products



Remsima



Truxima



Herzuma

Biopharmaceutical

Product	Reference Product	INN	Indications
Remsima SC	-	Infliximab	Rheumatoid Arthritis
Remsima / Inflectra	Remicade	Infliximab	Rheumatoid Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohn's Disease, Psoriasis
Truxima	Rituxan	Rituximab	Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Granulomatosis with Polyangiitis, Microscopic Polyangiitis
Herzuma	Herceptin	Trastuzumab	HER2-Positive Metastatic Breast Cancer, Early Breast Cancer, Metastatic Gastric Cancer

Small molecule

Product	Ingredient	Indications
Linezolid	Linezolid	Pneumonia, Skin and Skin Structure Infections, Vancomycin-resistant Enterococcus faecium Infections

R&D Pipeline

Antibody Biosimilars

Project	INN	Original	Indications	Status
CT-P39	Omalizumab	XOLAR®	Asthma, Urticaria	Research
CT-P17	Adalimumab	HUMIRA®	Rheumatoid arthritis, Psoriatic arthritis, IBD	Phase3
CT-P16	Bevacizumab	AVASTIN®	Metastatic Colorectal Cancer, Metastatic Breast Cancer, NSCLC	Phase3

New Antibodies

Project	Indications	Status
CT-P59	COVID-19	Research
CT-P27	Pandemic-Seasonal influenza	Phase2

IMDs

Project	Indications	Status
CT-G20	Cardiomyopathy	Clinical trial



CREVALUABLE COMPANY, CREATIVE COMPANY,
BEAUTIFUL COMPANY

CHONG KUN DANG

www.ckdpharm.com/en/home

Chong Kun Dang Pharmaceutical Corp. (CKD) was established in 1941 with a goal of supplying the best quality medicines. In 1968, CKD received US FDA approval for Chloramphenicol. Remarkably, CKD is one of the first Korean pharmaceutical companies to establish Research Center in early 1970's to accelerate the development of novel technologies and therapeutics. As a result, CKD has successfully launched two novel therapeutics, Camtobell for anti-cancer and Duvie for type 2 diabetes, and world's first NESP biosimilar, Nesbell.

Main Products



Category	Brand Name	Ingredients	Note
Oncology	Camtobell Inj	Belotecan	New Drugs
Type 2 diabetes	Duvie Tab	Lobeglitazone	New Drugs
Antihypertensive drugs	Dilatrend Tab	Carvedilol	
Immunology	Tarcobell Cap	Tarcrolimus	
Antihyperlipidemic agent	Lipilou Tab	Atrovastatin	
Nootropic Agents	CKD Gliatilin Soft Cap	Choline Alfoscerate	

CEO
YOUNG JOO KIM

Location
8 Chungjeong-ro, Seodaemun-gu, Seoul, Korea

Specialty
1. Anticancer New Drugs
2. Antidiabetic New Drugs
3. Autoimmune Diseases

Tel / Fax / E-mail
T. 82-2-2194-0300
F. 82-2-2194-0369
E. youngjookim@ckdpharm.com

R&D Pipeline

New Chemical Drugs/Biologics

CV & METABOLIC DISEASE

Diabetes (PPAR-γ agonist)
Dyslipidemia (CETP inhibitor)

ONCOLOGY

Ovarian Cancer, SCLC (Camptothecin analogue)
Liver Cancer (A3 adenosine receptor agonist)
Colorectal Cancer (VDA)
Multiple Myeloma (Pan-HDAC inhibitor)
NSCLC, Colorectal Cancer (Bi-specific antibody)

IMMUNOLOGY


SLE, Dermatomyositis (anti-INFα)
Autoimmune Disease (HDAC6 inhibitor)

CNS

Neurodegenerative Disease (HDAC6 inhibitor)

OTHERS

∞ Anemia (Darbepoetin-α)
∞ Ophthalmology (Ranibizumab)
Pain, Uremic Pruritus (Opioid κ receptor agonist)
HSDD (Hypoactive sexual desire disorder)
Rare Disease (HDAC6 inhibitor)



∞ Biologics / * In-licensed product



CORESTEM creates new hope for treatment of intractable diseases.

Corestem, Inc

www.corestem.com/en/

CEO
Kyung Suk Kim

Location
24, Pangyo-ro 25 beong-gil,
Bundang-gu, Seongnam-si,
Gyeonggi-do, Korea

Specialty
Stem Cell Therapy

Tel / Fax / E-mail
T. 82-2-497-3711
F. 82-2-6349-8666
E. corestem@corestem.com


CORESTEM is a bio-pharmaceutical company specializing in research and development of personalized stem cell therapies for incurable disease. We developed the world's first stem cell therapeutic product for ALS (Amyotrophic Lateral Sclerosis), name of Neuronata-R®. Corestem's research and development is focused on advancing preferred stem cell treatments for intractable diseases, driving scientific advancement, and expanding patient care offerings.

Main Products



	Product	Ingredient	Use
Neurological Disease	Neuronata-R®	Autologous bone marrow derived mesenchymal stem cell (lenzestocel)	Mitigation of amyotrophic lateral sclerosis (ALS) progression.

R&D Pipeline





CrystalGenomics, Inc.

www.crystalgenomics.com/en

CrystalGenomics is a commercial stage biopharmaceutical company dedicated to the R&D and commercialization of novel pharmaceuticals to address significant unmet medical needs in the therapeutic area of infectious disease, oncology and inflammatory diseases.

CrystalGenomics has a marketed product, Acelex (Polmacoxib), which has been approved by the MFDS and several export agreements has been signed with several countries.

In addition to Acelex, CrystalGenomics is developing several first-in class/best-in class drug candidates.

Main Products



Acelex Tablet



Acelex Capsule

Products (Ingredient/Formulation)	Use	Exporting Countries
Acelex (Polmacoxib) 2mg Capsule	Nonsteroidal anti-inflammatory drug for osteoarthritis	Turkey & MENA 19 countries, Brazil, Eurasian Economic Union (Russia, Belarus, Kazakhstan, Kyrgyzstan, Armenia)
Acelex (Polmacoxib) 2mg Tablet	Nonsteroidal anti-inflammatory drug for osteoarthritis	

R&D Pipeline

Area	Program	Indications	Preclinical	Ph 1	Ph 2	Ph 3
Pain/ Inflammation	CG-650	Acute/Chronic Pain				
	CG-651 ⁽¹⁾	Neuropathic Pain				
	CG-598 ⁽²⁾	Inflammatory Bowel Disease				
Anti-Infective	CG-549 ⁽¹⁾	MRSA		Global Clinical trial		
Oncology	Ivaltinostat ⁽²⁾	Pancreatic Cancer		MFDS/FDA Orphan Drug Designation		
	Ivaltinostat ⁽²⁾	MDS		MFDS Orphan Drug Designation		
	Ivaltinostat ⁽²⁾	AML		Global Clinical trial		
	Ivaltinostat + Anti-PD-1 Antibody	HCC ⁽¹⁾		Global Clinical trial		
	CG-806 ⁽¹⁾	AML, MCL, CLL		APTOSE BIOSCIENCES	Global Clinical trial	
Fibrosis	CG-750 ⁽²⁾	Fibrosis				

(1) First-in-class
(2) Best-in-class

CEO
Joong Myung Cho

Location
CrystatGenomics, Inc., 5th F,
Bldg A, Korea Bio Park, 700,
Daewangpangyo-ro, Bundang-
gu, Seongnam-si, Gyeonggi-do
13488, Republic of Korea

Specialty
1. Inflammatory disease
2. Oncology
3. Infectious disease

Tel / Fax / E-mail
T. 82-31-628-2720
F. 82-31-628-2701



The dream of prolonging life into reality

DAEHWA Pharm

www.dhpharm.co.kr

CEO
Byung-Tae No, Eun-Seok Kim

Location
24, Pangyo-ro 25 beong-gil,
Bundang-gu, Seongnam-si,
Gyeonggi-do, Korea

Specialty
New anticancer combination
drug, Incrementally modified
drug, Biosimilar, First generic

Tel / Fax / E-mail
T. 82-2-586-6451
F. 82-2-587-0566

Daehwa, with spirit of “serving society to create a better place for human being through pharmaceutical business”, has a goal to improve quality of life with respect for human life. Core technologies such as DHLASED, are used to develop drugs in various fields, to be a pioneer for new paradigm, and by cooperating with global partners, Daehwa is currently exporting products to 20 different countries. In 2017, Daehwa acquired German medical device and cosmetic company to expand to new area with its unique know-how on the aesthetic fields.

Main Products

Product (Ingredient/Formulation)	Use	Exporting Countries	Remarks
Methylol cephalixin lysinate	Antibiotics	-	Launched
Phloroglucinol	Antispasmodic	-	Launched
Diacerein	Osteoarthritis	Ecuador, HongKong	Launched
Warfarin sodium	Antithrombotic agent	Bolivia, Ecuador	Launched
Ginseng, Vitamin	Nutrient	Taiwan, Bolivia 외	Launched



Daewon Pharm. Co., Ltd.

www.daewonpharm.com/eng/main/index.jsp

Daewon Pharmaceutical's believe that customers is the most important core value of corporate management. Since Established in 1958 based on the founding philosophy of "partner for people to promise their healthy lives", we have effort to protect the healthy life of people as a company specialized in pure competent pharmaceutical company.

Daewon Pharm is a pharmaceutical company that based on its advanced facility & Plant, investment and excellent R&D capabilities, we have developed the 'Pelubi Tab', a new drug for the Korean & Global market.

Main Products

Category	Product	Molecule
Analgesic	Pelubi CR Tab.®	Pelubipirofen
	Pelubi Tab.®	Pelubipirofen
	Nerexone SR Tab.	Eperisone
Cardiovascular	Clow Tab.	Rosuvastatin
	Lipiwon Tab.	Atorvastatin
	Exombi Tab.	Varsartan/amlodipine
	TG Fenone Tab.	Choline Fenofibrate
	Twincombi Tab.	Telmisartan/amlodipine
	Tri-in-one Tab.	Telmisartan/amlodipine/Rosuvastatin
	Uptava Cap.	Pitavastatin/Fenofibrate
Gastrointestinal	Eswonamp Tab.	Esomeprazole
	Otilen F Tab.	Artemisia herb isopropanol soft extract(20→1)
Respiratory	Codaewon Forte Syr.	Dihydrocodeine/ammonium chloride /chlorpheniramine/dl-methylephedrine
	Beposta SR Tab.	Bepotastine
	Beposta SR Tab.	Bepotastine
	Elsteine Tab.	Erdosteine
Analgesic	Wontran ER Tab.	Acetaminophen/Tramadol
	Lyicaneuro ER Tab.	Pregabalin
	Freefol MCT Inj.1,2%	Propofol
Others	Renamezin Cap.	Spherical adsorptive carbon

R&D Pipeline

Category	Project Code	Indication	Stage
New chemical entity	DW-4301	Cardiovascular Disease	Phase I
	DW-4902	uterine disease	Phase I
Generic	DW-2801	Gastrointestinal disease	Phase I
	DW-5903	Cardiovascular Disease	Pre-Clinical
Incrementally modified drug	DW-1601	Respiratory Disease	Phase III
	DW-1807	Respiratory Disease	Phase I
	DW-1806	Metabolic Disorders	Phase I
	DW-1805	Metabolic Disorders	Pre-Clinical
	DW-8809	Gastrointestinal disease	Pre-Clinical
	DW-1804	Metabolic Disorders	NDA submit
	DW-1808	degenerative disease	Pre-Clinical
	DW-1809	degenerative disease	Phase I

CEO

Seung Ryel Baek

Location

386 cheonhoda-ro, Seong-dong-gu, Seoul #04808, Korea

Specialty

1. IMD (incrementally modified drug)
2. NCE (New chemical entity)
3. First Generic

Tel / Fax / E-mail

T. 82-2-2204-7000

F. 82-2-3436-4878



A global healthcare group dedicated to improving quality of life

Daewoong Pharmaceutical Co., Ltd.

www.daewoong.co.kr

CEO
Jeon Seng Ho

Location
Bongeunsa-ro 114-gil 12 Gang-
nam-gu Seoul 06170 Korea

Specialty
1. new chemical entities for
intractable disease
2. stem cell therapy for rare
diseases (cell & gene
therapy)
3. new formulation technology

Tel / Fax / E-mail
T. 82-2-550-8533
F. 82-2-550-8400
E. stomeve@daewoong.co.kr

Since 1945, we have grown into Korea's leading company in line with corporate philosophy of 'developing quality medicine to safeguard the people's health and contribute to a healthier society.'

With \$1.3B revenues, we have 8 manufacturing sites globally and branches in China, Japan, Indonesia, Thailand, Vietnam, Philippines, India and USA. We are the no.1 Korean player in Chinese GI market, and we acquired the no.2 Vietnamese company (Traphaco). We have the first Halal certified Indonesian bio facility and a POC center in India.

Main Products

Brands

Product name	Description
Ursa®	Liver diseases & dysfunction improvement
Bearse®	Multilayer digestives



Biologics

Product name	Description
Easyef® (EGF)	Diabetic foot ulcer, Acute wounds
Novosis® (rh BMP-2)	Dental sinus lift graft
Caretropin® (hGH)	Growth hormone deficiency
Eposis® (EPO)	Anemia in chronic kidney disease
Nabota® (Botulinum toxin)	Anti-wrinkles



Formulation

Product name	Description
Luphere® Depot	Peptide delivery system for prostate cancer
lostar	New combination drug for Hyperlipidemia/hypertension



R&D Pipeline

	Research	Pre-clinical	Phase I	Phase II	Phase III	NDA & Marketed
10 NCEs	DWJ215 Hearing loss	DWP212525 Pemphigus Vulgaris	DWN12088 IPF	DWP16001 Type2 Diabetes		Fexuprazan (NDA) Erosive Esophagitis
	DWJ816S002 Oncology	DWP213338 GvHD		DWP305401# Ulcerative colitis		
	DWJ816S003 Oncology	DWP17061 OA pain				
12 Biologics & 6 Stem cells	HL186 Immuno-oncology	DWP457 Long-acting Insulin	DWP706 Corneal wound	Nabota Square jaw	Nabota Anti-middle of Forehead wrinkle	NABOTA (US/EU) Glabellar lines
	HL187 Immuno-oncology	DWP820S001 Dementia	Furestem-RA† Rheumatoid arthritis	Furestem-CD† Crohn's disease	HL036† Dry eye syndrome	
	DWP458 Osteoporosis	DWP820S002 Cerebellar atrophy		HL161* Myasthenia gravis		
		DWP820S006 Severe acute pancreatitis		HL161* Graves's Ophthalmopathy		
		DWP700 Stroke		HL161* WAIHA		





GC Pharma(Former Green Cross Corp.)

GC Pharma has been a leading biotech company for developing innovative biotherapies including vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies.


GC Pharma developed the world's first vaccine against epidemic hemorrhagic fever "Hantavax" and the world's second vaccine for varicella zoster virus vaccine "Suduvax".

GC Pharma is also pursuing opportunities in rare diseases by developing therapies such as Hunterase (world's second ERT for Hunter syndrome). In 2019, GC Pharma's total revenue rose to KRW 1.369 trillion.

Main Products

Product Name / Active Substance	Pharmacological Effects	Exporting Countries	Remarks
1) I.V.-Globulin SN inj. / Human Intravenous Immunoglobulin	A-/Hypogammaglobulinemia Combined therapy with antibiotics for severe bacterial or viral infections Idiopathic thrombocytopenic purpura Guillain-Barre syndrome Kawasaki syndrome	Asia, Middle-East, Central & South America	Plasma Derivatives
2) Albumin inj.-GCC / Human Albumin Solution	For hypoalbuminemia and shock in acute hemorrhage from loss of albumin (burns, nephrotic syndrome, etc.) and low synthesis of albumin (hepatic cirrhosis, etc.)	Asia, Middle-East, Central & South America	Plasma Derivatives
3) Green-VIII inj. / Human Blood Coagulation Factor VIII	For the treatment of hemophilia A with supplies of blood coagulation factor VIII	Asia, Middle-East, Central & South America	Plasma Derivatives
4) GreenGene F inj. / Recombinant Coagulation Factor VIII	For the prevention and control of bleeding episodes and preoperative management in hemophilia A	Asia, Middle-East, Central & South America	Recombinant Product
5) Hepabig inj. / Human Hepatitis B Immunoglobulin	For prophylaxis of hepatitis B after exposure to HBsAg For prophylaxis of hepatitis B in neonates	Asia, Middle-East, Central & South America	Plasma Derivatives
6) I.V. Hepabig inj. / Human Hepatitis B Immunoglobulin	For prevention of recurrence of hepatitis B in patients with liver transplants	Asia, Middle-East, Central & South America	Plasma Derivatives
7) Sero-Tet inj. / Human Tetanus Immunoglobulin	For the prophylaxis of tetanus and the reduction of tetanus symptoms	Asia, Middle-East, Central & South America	Plasma Derivatives
8) GCFLU PFS inj. / Split Virion, Trivalent Inactivated Influenza Vaccine	For the prophylaxis against influenza	Asia, Middle-East, Central & South America	Vaccines
9) GCFLU Quadrivalent PFS inj. / Split Virion, Quadrivalent Inactivated Influenza Vaccine	For the prophylaxis against influenza	Asia, Middle-East, Central & South America	Vaccines
10) Varicella vaccine-GCC inj. / Live Attenuated Varicella Vaccine	For the prophylaxis against varicella	Asia, Middle-East, Central & South America	Vaccines
11) Hunterase / Idursulfase beta	For treatment (Enzyme Replacement Therapy) of Hunter Syndrome (Mucopolysaccharidosis II)	Asia, Middle-East, Central & South America	Recombinant Product
12) Neulapeg PFS Inj. / PEG-GCSF	For decrease the duration of severe neutropenia for patients receiving cytotoxic chemotherapy for solid tumor and malignant lymphoma	Asia, Middle-East, Central & South America	Recombinant Product

R&D Pipeline



CEO
Eun-Chul Huh

Location
107, Ihyeon-ro 3beon-gil,
Giheung-gu, Yongin-si, Gyeong-
gi-do 16924, Korea

Specialty

1. Plasma Derivatives
2. Vaccine
3. Recombinant protein

Tel / Fax / E-mail
T. 82-31-260-9300
F. 82-31-260-9491



Genexine, Inc.

CEO
Young Chul Sung, PhD

Location
700 Daewangpangyo-ro, Korea
Bio ParkBldg. B, Bundang-gu,
Seongnam-si, Gyeonggi-do
13488, Republic of Korea

Specialty
Cancer Immunotherapeutics,
DNA Therapeutic Vaccines,
Next Generation Long-acting
Biologics

Tel / Fax / E-mail
T. 82-31-628-3200
F. 82-31-628-3229
E. bd@genexine.com
ir@genexine.com

Genexine (KOSDAQ, 095700) is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics. Our goal is to bring to patients medicines that will transform their lives. hyFc platform and DNA therapeutic vaccine platform are our own core proprietary technologies, which are designed to drive the discovery of a wide range of differentiated therapeutics.

R&D Pipeline

GX-I7 (Long-acting IL-7)

Areas	Indication	Regimen	Non-clinical	Phase 1	Phase 2	Site
Immuno-Oncology	Healthy Volunteers	SAD		Completed		KR
	Solid Tumor	Mono		Ongoing 1b		KR
		Mono		Ongoing 1		CN
		Mono		Ongoing 1b/2a		KR/US
	Glioblastoma	TMZ Combo		Ongoing 1/2		US
	Triple Negative Breast Cancer	Pembrolizumab Combo		Ongoing 1b/2		KR/US
	Skin Cancer	Atezolizumab Combo		Ongoing 1b/2a		US

GX-188 (HPV DNA Therapeutic Vaccine)

Indication	Regimen	Non-clinical	Phase 1	Phase 2	Site
Cervical Cancer	Pembrolizumab Combo		Ongoing 1b/2		KR

GX-H9 (Long-acting hGH)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Adult Growth hormone Deficiency		Completed			KR/EU
Pediatric Growth hormone Deficiency		Completed			KR/EU

GX-G3 (Long-acting G-CSF)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Neutropenia		Completed			KR/EU

GX-E4 (Long-acting EPO)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
CKD-induced Anemia		Completed		Mutational Phase 3 on-going	ASEAN/AU

GX-G6 (Long-acting GLP-1)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Type 2 Diabetes		Completed	Phase 2 IND Approved		EU

GX-G8 (Long-acting GLP-2)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Short Bowel Syndrome		Phase 1 IND Approved			EU

GX-P1 (Long-acting PD-L1)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Autoimmune diseases organ transplantation		Phase 1 IND Approved			KR



"The Health Innovator"
as Korea's leading global total healthcare company.



www.handok.co.kr/eng

HANDOK. Inc.

Handok has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies. For more information, please visit www.handok.co.kr.

Main Products

	Product	Indication	Main Export
Endocrine system	Amaryl M, Amaryl MEX	Glimepiride Metformin	Thailand, Dubai, Russia, Hungary, UAE, Philippines, Singapore etc.
	Tenelia M	Teneligliptin, Metformin	-
	Daonil tab.	Glibenclamide	
Integumentary system	Esperson oint. 0.25%	Desoxymethasone Semi-solid	Thailand, Taiwan
Central nervous system	Frisium tab. 10mg	Clobazam	
Cardiovascular system	Lasix tab.	Furosemide	Thailand, Taiwan, Philippines
Osteoarthritis and muscular pain	KETOTOP Plaster	Ketoprofen	Myanmar, Vietnam, Singapore, Kazakhstan, Malaysia etc.

R&D Pipeline

Therapeutic Area	Project	Classification	Indication	Dis.	Pre clinical	Phase I	Phase II	Phase III	Remarks
Orphan	HL2356 (GX-H9)	Biologics	Adult Growth Hormone Deficiency				■		<ul style="list-style-type: none"> • Genexine Partnered • Supported by Government Funding (KDDF**)
			Pediatric Growth Hormone Deficiency				■		
Oncology	HL5101	Chemical	Cancer		■				<ul style="list-style-type: none"> • CMG Pharm. Partnered • Supported by NOV***
Ophthalmology	HL3501	Chemical	Glaucoma	■					<ul style="list-style-type: none"> • Supported by Government Funding (KDDF**)
Diabetes/ Metabolism	HD-P550	IMD*	Diabetes + Hyperlipidemia		■				
	HD-C715	Chemical	Diabetes	■					
Cardio Vascular	DENEX	Resistant Hypertension	Medical Device				■		<ul style="list-style-type: none"> • CE Mark approved (2016yr)
CVD/Infectious Disease	Nanocon RST kit	Medical Device_IVD (IVD: in-vitro Diagnostic)	CVD/Infectious Disease				■		

*IMD: Incrementally Modified Drug

**KDDF: Korea Drug Development Fund

***NOV: National OncoVenture

■ Biologics ■ Small Molecule ■ Medical Device

CEO
Young Jin Kim, Jin Ki Baik

Location
132, Teheran-ro, Gangnam-gu, Seoul, 06235, Korea

Specialty
1. Anti-diabetics New Chemical Entities
2. Anti-diabetics Diabetes Incrementally Modified Drugs
3. Anti-arthritis Plaster

Tel / Fax / E-mail
T. 82-2-527-5114
F. 82-2-527-5001
E. Handok@handok.com



Protecting the precious human life from various forms of disease

HANLIM PHARM. CO., LTD.

<http://www.hanlim.com/eng>

CEO
Jae Yoon Kim, Jung Jin Kim

Location
42, Seocho-Daero 52 Gil,
Seocho-Gu, Seoul 06634
Republic of Korea

Specialty
R&D, Manufacturing of API/
BPIs and Pharmaceutical
Product

Tel / Fax / E-mail
T. 82-2-3489-6000
F. 82-2-3489-6101
E. master@hanlim.com

With the corporate mission, "Protecting the precious human life from various forms of diseases", HANLIM has consistently endeavored to improve the health standards of people, and we have become one of the leading pharmaceutical companies in Korea. In 1993, the future-oriented GMP factory was completed together with the founding of the central research center. We continue to make a great investment in accumulating advanced technologies and manufacturing facilities lately to enhance human health.

Main Products





Product Name	Active Ingredient(s)	Category	Remark
T-Sporin Eye Drops	Cyclosporin 0.5mg	Ophthalmic	IMD Product
Nasaflex Nasal Spray	Mometasone furoate 0.5mg, Azelastine HCl 1.4 mg	Allergy&ENT	IMD Product
Risenex Plus Tab.	Sodium Risedronate 35mg, Cholecalciferol 5,600IU	Endocrine	IMD Product
Dages Cap.	Pepsin 25mg, Papain 50mg, Diastase 15mg, Cellulase 15mg, Pancreatin 50mg, Pancrelipase 13mg, UDCA 25mg	Digestive	

R&D Pipeline



Mesenchymal stem cells

Product	Indication	Pre-clinical	Clinical phase		
			1	2	3
HL401	Systemic Lupus Erythematosus				

NCE (New Chemical Entity) Discovery

Product	Indication	Pre-clinical	Clinical phase			NDA
			1	2	3	
HL301	Acute Bronchitis					
HL217	AMD					
HL237	Rheumatoid Arthritis					
HL237A	Liver Transplantation					

IMD (Incrementally Modified Drug)

Product	Indication	Pre-clinical	Clinical phase			NDA
			1	2	3	
Lumino- mark Inj.	Breast Lesion Surgery Marker					
HL-TOF	Rheumatoid Arthritis					



Hanmi Pharmaceutical Co., Ltd.

Hanmi Pharm is a global pharmaceutical company focused on the development and commercialization of new pharmaceutical products, with presence in Korea and China. The company's R&D efforts focus on three main areas: 1) new biologics based on LAPSCOVERY platform in diabetes, obesity, NASH and rare diseases; 2) novel targeted agents and 3) novel bispecific antibodies based on PENTAMBODY platform for immuno-oncology and targeted therapy. Hanmi has multiple partnerships and strategic collaborations with leading MNCs and Chinese biopharma companies.

Main Products

Category	Product	Use	Ingredient	Exporting countries
Cardiovascular disease	Amosartan	Hypertension	Amlodipine	CIS
	Amosartan Plus	Hypertension	Amlodipine + Losartan + Chlorthalidone	LATAM
	Amosartan Q	Hypertension, dyslipidemia	Amlodipine + Losartan + Rosuvastatin	LATAM
	Rosuzet	Dyslipidemia	Ezetimibe + Rosuvastatin	CIS, LATAM, SEA
	Amodipin	Hypertension	Amlodipine camsylate	-
	Rovelito	Hypertension, dyslipidemia	Irbesartan + Atorvastatin	LATAM
	Carnitil	Alzheimer's disease, dementia	Acetyl-L-carnitine hydrochloride	-
	Pidogul	Antiplatelet	Clopidogrel napadisilate	MALAYSIA
Gastrointestinal disease	Esomezol	GERD, Gastric ulcer	Esomeprazole strontium	-
Urology	Palpal	Erectile dysfunction	Sildenafil	JAPAN
	Gugu	Erectile dysfunction	Tadalafil	JAPAN
	HANMI TAMS	BPH	Tamsulosin hydrochloride	-
Neurology	Naxozol	Anti-inflammatory	Naproxen + Esomeprazole	-
Ophthalmology, etc	Hyalumini eye drop	Artificial tear, Sjögren's syndrome	Sodium hyaluronate	-
	Rabone D	Osteoporosis	Raloxifene + cholecalciferol	-

CEO
Jong-Soo Woo, Se-Chang Kwon

Location
14, Wiryeseong-daero, Songpa-gu, Seoul, 05545, Korea

Specialty
R&D based pharmaceutical products

Tel / Fax / E-mail
T. 82-2-410-9114

R&D Pipeline

	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
Obesity/ NASH/ Diabetes	LAPS Glucagon Combo HM14320 Obesity/Diabetes/NASH	LAPSTriple Agonist HM15211 NASH	LAPSGLP/GCG HM12525A Obesity	LAPSExd4 Analog Efeglenatide Diabetes SANOFI	
	LAPS Insulin Combo HM14220 Diabetes SANOFI	LAPS Glucagon Analog HM15136 Obesity			
	LAP Insulin148 HM12480 Diabetes	LAPS Insulin HM12460A/HM12470 Diabetes			
Oncology	EZH1/2 Inhibitor Solid tumor	Pan-RAF Inhibitor Belvarafenib Solid tumor Genentech	Pan-HER Inhibitor Pozotinib Solid tumor SPECTRUM	Oraxol™ Pacitaxel+encequidar Breast cancer, solid tumor Astellera	LAPSGCSF Analog Eflapegrastim Neutropenia SPECTRUM
	LSO1 Inhibitor SCLC, AML	FLT3 Inhibitor HM43239 AML	Oratecan™ Irinotecan+encequidar Solid tumor Astellera		
	ADOR Antagonist Solid tumor	PD-1/HER2 BsAb BH2950 Solid tumor Innovent	Oradoxel™ Docetaxel+encequidar Solid tumor Astellera		
	GBM Stem Cell Therapy HM21001 Glioblastoma	FLX475 (CCR4 Inhibitor) Solid tumor RAPT			
	Immuno-oncology BsAb Solid tumor Purigen				
	PD-L1/CD47 BsAb Solid tumor, Hematologic cancers				
	LAPS ASB HM15450 Mucopolysaccharidosis	LAPS Glucagon Analog HM15136 Congenital Hyperinsulinism	LAPShGH Efeglenatropin GH deficiency Astellera		
Rare Diseases/ Other		LAPSGLP-2 Analog HM15912 Short Bowel Syndrome	Luminate® Integrin inhibitor DME Astellera		
		Luminate® Integrin inhibitor Retinitis Pigmentosa Astellera	BTK Inhibitor HM71224 Autoimmune disease		



Helixmith Co., Ltd.

CEO
Sunyoung Kim

Location
21, Magokjungang 8-ro 7-gil,
Gangseo-gu, Seoul 07794,
Korea

Specialty
plasmid DNA-based gene
therapy


Tel / Fax / E-mail
T. 82-2-2102-7100
F. 82-2-887-0011
E. contact@helixmith.com

Founded in 1996, Helixmith has been dedicated to research in gene therapy for over 20 years. Led by Sunyoung Kim and his lab in Seoul National University, the Helixmith team has developed an extremely powerful gene expression system and has tested it in various therapeutic areas. The company is currently headquartered in Seoul, Korea; our clinical development and manufacturing activities are based in San Diego, California in the US. In particular, we co-own a cGMP-ready DNA production facility, Genopis, Inc., an affiliated CDMO in San Diego. Genopis serves both Helixmith and external customers in need of DNA.

Main Products

Product	Target Disease	Technology	Country	Development Stage
VM202	Diabetic peripheral neuropathy	Gene therapy	US	Phase 3 / FDA RMAT
	Diabetic foot ulcer	Gene therapy	US	Phase 3
	Ischemic heart disease	Gene therapy	Korea	Phase 2
Orphan Drug	Amyotrophic lateral sclerosis	Gene therapy	US	Phase 2 / FDA Fast Track
VM206	Breast cancer	DNA vaccine	Korea	Phase 2

R&D Pipeline





HK inno.N Corporation

As a well-established local pharma in prescription drugs and Health & Beauty, inno.N(Fomer CJHC) is at its preparation for the future by allocating resources to R&D for new drugs, biologics mainly in liver, cancer, and immune disease areas.

In 2019, we launched **K-CAB® Tab. (Tegoprazan)**, a new drug for GERD, as Korea's 30th new drug. K-CAB® Tab. is loved in Korea for its EE, NERD and GU indications, and is expanding into 22 countries including China and Latin America, and is spreading its R&D capabilities to the global market.

Main Products

Product	Indication & Use	Exporting Countries
K-CAB Tab. (Tegoprazan)	Gastroesophageal reflux disease (GERD)	China, Vietnam, Latin America 22 countries including Mexico
Epokine Inj.(rh-EPO)	Anemia of hemodialysis patients with end-stage renal disease	Asia, Latin America and Africa
Vancorin Inj. (Vancomycin)	Serious, life-threatening infections by gram-positive bacteria	Asia
Tapocin Inj. (Teicoplanin)	Serious infections by gram-positive bacteria	Asia
Moveloxin I.V. solution bag (Moxifloxacin)	Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia and so on	Asia
Cinezolid I.V. solution bag (Linezolid)	Vancomycin-resistant Enterococcus faecium infections	-
Citopcin I.V. Solution bag (Ciprofloxacin)	Infections caused by microorganism	Asia
Levotopcin I.V. Solution bag (Levofloxacin)	Infections caused by microorganism	-
Calmtop Inj. (Irinotecan)	Colorectal cancer	-
Pemta Inj. (Pemetrexed)	Pleural mesothelioma and non-small cell lung cancer	-
OmapOne Lipid Inj. bag (Fish/MCT/Soybean/Olive oil)	Supplying energy, essential fatty acids and omega-3 fatty acids to patients.	-
OmapOne Peripheral Inj. bag (Lipid, Amino acid, Glucose)	Supplying Lipid, Amino acid and Glucose to patients	Asia
Atomet XR Tab. (Atorvastatin/Metformin)	Type2 Diabetes/Hyperlipidemia	-
Machkhan Tab. (Candesartan/Amlodipine)	Hypertension	-
CONDITION (Hyaluronic acid)	Anti-hangover drink	China, Japan
HongSamJin Gold (Red Ginseng drink)	Outstanding energy drink produced with 6-year-old red ginseng	China

R&D Pipeline

	Pipeline	Target Indication	DS	PC	Clinical Trial			NDA	MKT	Partnering availability
					PI	PII	PIII			
NCE	IN-A002	Autoimmune disease	██████████							
	IN-A011	Nutrition	██████████							
	A2AR inhibitor	Cancer	██████████							
	FER/T inhibitor	Cancer	██████████							
	DCLK1 inhibitor	Cancer	██████████							
	HSD inhibitor	NASH	██████████							
IMD	IN-C008	Hypertension / Hyperlipidemia	██							Global
	IN-C009	Type 2 Diabetes	████████████████████							
	IN-C010	Type 2 Diabetes	████████████████████							
	IN-C011	Type 2 Diabetes	██							
	IN-C001	Gastroesophageal reflux disease	██████████							
Biologicals	IN-B001	Hand, Foot & Mouth Disease	████████████████████							
	IN-B002	Smallpox	██████████							
	Pneumococcal	Pneumonia	██████████							
	IN-B004	Autoimmune disease	██████████							
	TANKIO	Cancer	██████████							

CEO
Seok Hee Kang,
Sang Hyun Yoon

Location
Pine Avenue Tower A, 100,
Euljiro, Jung-gu, Seoul, 04551,
Korea

Specialty
ETC (CVs, Antibiotics, IV Solution, Oncology, Endocrinology, Nephrology&Urology, Gastro Intestinal, Musculoskeletal, Respiratory, Others) & Health functional products

Tel / Fax / E-mail
T. 82-2-6477-0000
F. 82-2-6477-0698
E. HKIN_business@inno-n.com



Total Healthcare Group which provides medical solution
for human being's health



www.huons.com/eng/

HUONS CO., LTD.

CEO
Key-An, UM

Location
253 C-902 Pangyo-ro Bundang-
gu, Sungnam Gyeonggi-do
(Sampyeong-dong, InnoValley)

Specialty
1. Liver disease NCE
2. Eye disease IMD
3. First-generic

Tel / Fax / E-mail
T. 82-2-854-4700
F. 82-2-6455-0740

Huons is one of the fastest growing company manufacturing quality finished pharmaceutical product since 1965 and possess cGMP standard of manufacturing site. Products are fully under control by strict quality system from global authorities including JAPAN and USA. For the last 60 years, we have continuously improved the business performances and it is keep ongoing. For more information, please visit our website www.huons.com or you can directly reach us by "CONTACT US" information.

Main Products

Product name	Composition	Use	Exporting Countries
Medicaine Inj.	Lidocaine HCl, Epinephrine Bitartrate	Dental Anesthesia	Japan etc.
Lidocaine Inj. 1%	Lidocaine HCl	Local Anesthesia	US etc.
Clacier Eye Drop	Cyclosporine	Eye drop for dry eye	Peru etc.
Hutox Inj. 100 Units	Botulinum Toxin	Glabellar lines	Panama etc.
Humia Inj.	Hyaluronic Acid	Osteoarthritis	Mexico etc.
Sodium chloride Inj.	Sodium chloride		US etc.

R&D Pipeline

		Indication	Development Phase					
			Discovery	Preclinical	Phase I	Phase II	Phase III	NDA
NCE	HUC1-259	Liver disease	<div></div>					
	HUC1-288	Heart failure	<div></div>					
IMD	HUC2-007	Dry eye syndrome	<div></div>					
	HUC2-255	Diabetes	<div></div>					
	HUC2-287	Allergic conjunctivitis	<div></div>					
BIO	HGB1-001	Lateral periorbital line	<div></div>					
	HGB1-001	Upper limb spasticity	<div></div>					
	HUB1-023	Dry eye syndrome	<div></div>					



HYUNDAI Pharm. Co., Ltd.

www.hyundaipharm.co.kr/english

HYUNDAI Pharm. was founded in 1965 as a pharmaceutical company with the corporate philosophy of "Contributing to the improvement of the health of mankind" based on the philosophy of the CEO who aims at the esteem of human respect and transparent corporate spirit. As a global R&D company, we aim to fulfill our responsibilities for improving public health by focusing on developing new drugs and incrementally modified drugs through continuous investment.

Main Products

Product name	Active ingredients	Indications
Minoxyl - 3%, 5% Solution - 3%, 5% Gel	Minoxidil	Androgenetic alopecia
Minoxyl complex Solution 5%	Minoxidil, Vitamin V6 / E, L-menthol	Androgenetic alopecia
Tenormin Tab.	Atenolol	Hypertension, Angina Pectoris
Uremine Tab.	Desmopressin acetate	Nocturnal enuresis
Mirtapin Tab.	Mirtazapine	Major depressive disorder
Mirap Tab. / ER Tab.	Pramipexole HCl	Parkinson's disease
Hipezil Tab.	Donepezil HCl	Alzheimer's disease
Dimantin Tab.	Memantine HCl	Alzheimer's disease
Tamirin SR Tab.	Galantamine HCl	Alzheimer's disease
Pemiosal Tab. / Dry Syrup	Pemilost potassium	Bronchial Asthma, Allergic Rhinitis
Surfolase Cap. / CR Tab.	Acebrophylline	Acute & chronic Bronchitis
Levotuss Tab. / Syrup	Levodropropizine	Acute & chronic Bronchitis
Clinium Vaginal Tab.	Dequalinium Chloride	Bacterial & Candida Vaginitis

CEO
Sang-Joon, Lee

Location
Hyundai Pharm Bldg, Bonge-
unsa Street 135, Gangnam-Gu,
Seoul

Specialty
1. NCE - Diabetes
2. IMD – Fixed dose combina-
tion of Alzheimer's disease
3. IMD – Fixed dose combina-
tion of Respiratory disease

Tel / Fax / E-mail
T. 82-2-1666-9979
F. 82-2-2693-7628
E. jhhwang@hdpharm.co.kr

R&D Pipeline

	CODE	PROJECT	INDICATION	Disco- very	Pre- clinical	Phase I	Phase II	Phase III	NDA
NCE	HDNO-1605 [HOB-047]	HD-6277 Novel antidiabetics	Type-2 Diabetes						
	BPDO-1603 [BPS-034]	New fixed-dose combination	Senile disease						
	HDDO-1728	New dosage form	Senile disease						
IMD	HDDO-1756	New fixed-dose combination	Endocrine disease						
	HDDO-1801	New fixed-dose combination	Respiratory disease						

ILDONG PHARMACEUTICAL CO., LTD.

A leading global group that helps people live healthier and happier lives.



www.ildong.com/eng

Ildong Pharmaceutical Co., Ltd.

CEO
Paul Woong - sup Yun

Location
2, Baumoe-ro 27-gil, Seocho-
gu, Seoul, Korea

Specialty
1. Ethical drug/Over-the-counter drug(Vitamins, Probiotics)
2. Antibiotics
3. Anticancer drug

Tel / Fax / E-mail
T. 82-2-526-3114
F. 82-2-526-3030

Since Ildong Pharmaceutical Group was founded in 1941 under the philosophy of 'pharmaceuticals are rooted in humans', we have created and shared significant value for health and prosperity throughout many years and will continue this endeavor. Ildong has become one of the leading pharmaceuticals in South Korea with powerful brand lineups including Aronamin, Biovita, and other major OTC products. We developed robust product pipelines for ethical drugs using our advanced technologies and diverse strategic partnerships.

Main Products

Category	Brand	Features
Ethical drug	Besivo	New drug for chronic hepatitis B treatment
	Pirespa	Idiopathic pulmonary fibrosis drug
	Flumarin	South Korea's widely-used antibiotic
	Sermion	Cerebral blood flow enhancer
	Telostop	Drug for hypertension and hyperlipidemia treatment(Telmisartan, Rosuvastatin)
	Twotops Plus	3-ingredient combination drug for hypertension treatment(Telmisartan, Amlodipine, Hydrochlorothiazide)
Over-the-counter drug	Telostop Plus	3-ingredient combination drug for hypertension and hyperlipidemia treatment (Telmisartan, Amlodipine, Rosuvastatin)
	Generic	Gastric acid inhibitor(Rabeprazole)
	Aronamin brand	Multivitamin
Quasi-drug, medical device	Exeramine	High-content vitamin supplement
	Prepain	Hemorrhoids treatment(ointment/suppository)
Health functional food	Meditouch	Moist wound healing dressing
	MyNi	My nutrition information, health functional food brand
Beverage	gQlab	Patented quadruple-coated probiotics
	Arogold D	Benefits of sunlight(Vitamin D) in a beverage
Cosmetics	First Lab	A cosmeceutical brand made with Ildong Pharmaceutical's knowhow

R&D Pipeline

■ In-house ■ In-licensed ■ IMD (Fixed dose combination) ■ Open Innovation (O.I.)

Type	Indication	MOA	Lab code	Phase					Current Status	Partner(s)
				Preclinical	Phase 1	Phase 2	Phase 3	Approval		
Open Innovation	Solid Tumor	PARP-1* inhibitor	IDX 1197						P1 ongoing	National OncoVenture
	PD*	iCp-Parkin	CV-06						Preclinical	Cellivory (KOR)
In-house	AMD*	Lucentis biobetters	ID0052						Preclinical ongoing	
	Solid Tumor	Avastin biobetters	ID0076						Preclinical ongoing	
In-licensed	Acute Migraine	5-HT 1F inhibitor	Lasmiditan					US	FDA Approval	Eli Lilly (US)
	CLL*	Rituximab biobetters	TG-1101					US	BLA Submission ready	TGTX (US)
IMD (FDQ)	Hyperlipidemia	Rosuvastatin/Fenofibrate	ID-RF						Pre-registration w/ MFDS*	

* PARP : Poly ADP-ribose polymerase *AMD : Aged related Macular disease *CLL : Chronic lymphocytic leukemia *MFDS : Ministry of Food and Drug Safety * PD: Parkinson's Disease



ISU ABXIS CO., LTD.

www.abxis.com/eng

ISU ABXIS is a biopharmaceutical company founded in 2001 with a desire of being an axis of therapeutic antibody as its names stands for ABXIS = AntiBody + aXIS. Beginning with the successful development and market launch of the Korean first therapeutic antibody Clotinab® in 2007, ISU ABXIS has established its own biotherapeutics development technologies and led Korean biopharmaceutical industry. ISU ABXIS will be dedicated to improving the lives of patients with cancers and incurable diseases.

Main Products



Therapeutic Area	Product	Generic Name	Major Market
Rare Disease	Abcertin®	Imiglucerase	Korea, Iran
	Fabagal®	Agalsidase beta	Korea
Cardiovascular	Clotinab®	Abciximab	Korea, Turkey

R&D Pipeline

Category	Project	Generic Name	Indication	Development Status				
				Discovery	Non-clinical	Phase 1	Phase 2	Phase 3
Novel	ISU104	-	ErbB3 positive cancers (head and neck, etc)	[Progress bar]				
	ISU304	Dalcinonacog alfa	Hemophilia B	[Progress bar]				
Bio-similar	ISU305	Ecuzumab	Paroxysmal Nocturnal Hemoglobinuria	[Progress bar]				
	Abcertin®	Imiglucerase	Gaucher's Disease	[Progress bar]				
	ISU106	Nivolumab	Various Cancers	[Progress bar]				

CEO
Seok Joo Lee

Location
Global R&D Center Building
C 5th Fl, 22 Daewangpangyo-ro, 712 Beongil, Bundang-gu, Seongnam-si, Gyeonggi-do 13488

Specialty
1. Novel biological cancer drugs
2. Biosimilars in rare diseases

Tel / Fax / E-mail
T. 82-31-696-4700
F. 82-31-696-4690
E. abxis@isu.co.kr



Innovative and Responsible

Janssen Korea

www.janssen.com/korea

CEO
Jenny Zheng, Lee Jung-Hee

Location
25F LS-Yongsan Tower, 92
Hangangdaero, Yongsan-gu,
Seoul, Korea

Specialty

1. Oncology new drug – small & large molecules, advanced therapy
2. Autoimmune disease new drug – small & large molecules
3. Infectious Disease chemical new drug & Vaccine biological new drug

Tel / Fax / E-mail
T. 82-2-2094-4500
F. 82-2-2094-4570
E. hsuh2@its.jnj.com

Janssen Korea, the Korean branch of the pharmaceutical division of Johnson & Johnson, started as a joint company with Yuhan Corporation in 1983. For the last 30 years, it has been committed to provide useful medicines for the treatment of diverse diseases.

We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Main Products

Therapeutic Area	Product	Ingredient	Indication
Neuroscience	Invega Sustenna	Paliperidone palmitate	Schizophrenia
	Invega Trinza	Paliperidone palmitate	Schizophrenia
Oncology	Velcade	Bortezomib	Multiple Myeloma, Mantle Cell Lymphoma
	Darzalex	Daratumumab	Multiple Myeloma
	Imbruvica	Ibrutinib	Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
	Zytiga	Abiraterone acetate	Metastatic Castration-Resistant Prostate Cancer
Infectious Disease	Sirturo	Bedaquiline	Multi-Drug Resistant Tuberculosis
Pulmonary Hypertension	Opsumit	Macitentan	Pulmonary Hypertension
Pain	Ultracet	Tramadol	Moderate to severe Pain
	Nucynta	Tapentadol	Severe Pain
Immunology	Simponi	Golimumab	Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
	Remicade	Infliximab	Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis
	Stelara	Ustekinumab	Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis
	Tremfya	Guselkumab	Psoriasis

R&D Pipeline

TA	Project/Product	Indication	Progress in Phase 2	Progress in Phase 3
Immunology	TREMFYA [®]	Psoriatic arthritis, Crohn's Disease		✓
	SIMPONI [®]	Pediatric Ulcerative Colitis		✓
	STELARA [®]	Lupus		✓
Oncology	erdafitinib	Non-muscle Invasive Bladder Cancer (NMIBC)	✓	
	apalutamide	Prostate cancer		✓
	niraparib	L3 Prostate cancer metastatic castration-resistant	✓	
	Lazertinib / JNJ-6372	Non Small Cell Lung Cancer	✓	
	BCMA CAR-T	Relapsed refractory multiple myeloma, genetic engineered cell therapy	✓	
Neuroscience	SPRAVATO [®]	Major depressive disorder at imminent risk for suicide		✓
	ponesimod	Multiple sclerosis		✓
Infectious Disease	pimodivir (JNJ-3872)	Influenza A		✓
	VAC52150	Monovalent Ebola Virus Vaccine		✓
	VAC89220	HIV Prevention Vaccine		✓
Pulmonary Hypertension	OPSUMIT [®]	Aged ≥2 to <18 years with Pulmonary Arterial Hypertension, Chronic thromboembolic pulmonary hypertension		✓
	UPTRAVI [®]	Chronic thromboembolic pulmonary hypertension		✓



JW Pharmaceutical

www.jw-pharma.co.kr/pharma/en/main.jsp

JW group Provides pharmaceuticals vital for maintaining the lives of patients such as anticancer drugs and antibiotics, and has developed into a leading pharmaceutical company and global manufacturer of I.V. Solutions.

For 75 Years ever since its foundation in 1945, JW group focuses on healthcare, ETC, OTC, diagnostics and medical equipment. Based on new technologies and services for healthy lives of human beings, JW group has built up strong sales network across the country and superior pipelines in I.V. solutions, antibiotics, oncology, cardiology, rheumatology and gout.

Main Products

1. Finished Product

- Carbapenem Antibiotics
- General I.V Solutions & Other Sterile Solutions
- Antimicrobial & Antifungal Agents
- Topical
- Agents for Antibiotics
- Amino Acid Solutions
- Gastrointestinal Agents
- Multivitamins
- Miscellaneous

2. API (Active Pharmaceutical Ingredient)

- Carbapenem Antibiotics: Imipenem/Cilastatin
- Anti-fungals: Ketoconazole, Itraconazole, Fluconazole
- Chiral Products for Custom Synthesis & Specialty Amino Acid
- Miscellaneous

R&D Pipeline

	Preclinical		Phase 1	Phase 2	Phase 3	Registration
Oncology	Project A1 WNT inhibitor	Project B1	CWP291 WNT inhibitor			
	Project B2	Project B3		CreaVax-BC GBM*	CreaVax-HCC HCC*	CreaVax-RCC RCC*
	Project B4					
Immune diseases	Project A2 WNT inhibitor	Project B5	JWP1601 H4R antagonist	URC102 Anti-gout		
Cardiovascular and Metabolic diseases						LIVALO
				LIVALO E		LIVALO V
						J-DART
Regenerative medicine	CWL080061	Project A3 WNT activator				
Orphan	Project A4 WNT activator			HEMLIBRA Hemophilia		
Eye diseases	Project A5 H4R antagonist					

*GBM : glioblastoma multiforme *HCC : Hepatocellular carcinoma *RCC : Renal Cell Carcinoma

CEO
SHIN YOUNG SUB,
LEE SEUNG RYLL

Location
2477, Nambusunhwan-ro,
Seocho-gu, Seoul, 06725,
Korea

Specialty
I.V-solutions, antibiotic,
cardiovascular, urology, gas-
trointestinal, nephrology and
anticancer

Tel / Fax / E-mail
T. 82-2-840-6777
F. 82-2-831-8351



The best beyond the first



KOLMAR KOREA

www.kolmar.co.kr/eng/

CEO
Ho Kyoung Lee

Location
245, Sandan-gil, Jeonui-myeon,
Sejong, 30003, Korea

Specialty
1. First generic and
incrementally modified drug
2. PreMix Injection
3. Topical (ex. Nail Lacquer)

Tel / Fax / E-mail
T. 82-2-515-0150

Since its establishment in 2002, Kolmar Korea offers one-stop CMO service. Our facility is KGMP certified (PIC/S GMP) with excellent capacity and quality management. Kolmar is one of the leading CMO companies, equipped to produce all dosage forms, for diverse indications based on R&D capacity. Innovative Lid-cap (Liquid filling in hard capsules) product is representative item of our one and only technique. With unique strength, Kolmar is broadening the scope to Worldwide beyond Korean market.

Main Products

Indication	Product Name	API	Main Market
Circulatory /Cardiovascular	Hiforge Tab	Valsartan, Amlodipine	HongKong
	Telopin Tab	Telmisartan, Amlodipine	
	Lipar Tab	Atorvastatin	HongKong
Endocrine System Gastro-Intestinal	Febuxt Tab	Febuxostat	Macau, Cambodia
	Nexpesol Tab	Esomeprazole	HongKong, Macau
NSAIDS	Painless Tab	Acetaminophen, Tramadol HCl	
	Celecoxib Cap	Celecoxib	HongKong
Respiratory	Pelium Syrup, Tab	Pelagonium Sidoides	Georgia
Dermatologicals	Ciclopirox Nail lacquer	Ciclopirox	Peru
	Prosol Ointment, Lition	Clobetasol Propionate	Cambodia
Infusion	Para-K	Acetaminophen	
	Suppramin	Amino acid	
Lid-cap (LiquidinHardcap)	Colin-K Lidcap	Choline alfoscerate	

Dosage Form	Description
Oral Solids	Tablet, Hard Capsule, Powder
Sterile	Injection (ampoule), Infusion, Eye drops, Lyophilized Injectables
Oral solutions	Syrup, Suspension
Topical	Ointment, Cream, Lotion, Solution, Nail Lacquer
Quasi Drug	Toothpaste, Gargle, Sanitizer
Lid-cap	Liquid filling in Hard Capsules (Innovative tech of Kolmar)

R&D Pipeline

Project	Drug	Indication	Product development					
			Research	Preclinical	PI	PII	PIII	Market
New Drug	KKM-162	inflammatory bowel disease						
	NDR-171(Herbal)	atopic dermatitis						
	NDR-171(Chemical)	atopic dermatitis						
	NDR-172	antitussive expectorants						
Incrementally modified drug	KKM-174-A	diabetes						
	KKM-174-C	diabetes						
	KKM-174-D	diabetes						
	KKM-181-A	hypertension						
	KKM-181-C	hypertension						
	KKM-183-A	antithrombotic						
	KKM-184-A	diabetes						
	KKM-184-D	diabetes						
	KKM-186-C	hypertension						
	KKM-191-D	diabetes						



Korea Otsuka Pharmaceutical Co., Ltd.

www.otsuka.co.kr/introduction_en

Korea Otsuka Pharmaceutical supplies excellent and innovative pharmaceutical and healthcare products. At a multinational pharmaceutical company equipped with large-scale production facilities in Korea, we contribute to the growth of national economy through domestic production as well as export. With understanding of customers, markets and social responsibilities, we are fulfilling our role and mission to become a company contributing to the healthy life of Koreans.

Main Products

Category	Product	Generic name	Export
CNS	Abilify Tab	Aripiprazole	EU, Hong Kong, Thailand, Indonesia, Philippine
	Abilify OD Tab		
	Abilify Maintena Inj		
CV	Pletaal Tab	Cilostazol	Japan, China, Indonesia
	Pletaal SR Cap		
	Samsca Tab	Tolvaptan	Thailand, Philippine, Indonesia, Vietnam
GI	Mucosta Tab	Rebamipide	Japan, China, Indonesia
ONC	Busulfex vial	Busufan	
	Iclusig Tab	Ponatinib	
PUL	Delyba Tab	Delamanid	

CEO
Moon, Sung-ho

Location
(06227) 226, Yeoksam-ro,
Gangnam-gu, Seoul, Republic
of Korea

Specialty
1. Chemical drug of CNS category
2. Chemical drug of Oncology category
3. Orphan drugs & First in class products

Tel / Fax / E-mail
T. 82-2-3287-9000
F. 82-2-3287-9069
E. otsuka@otsuka.co.kr

R&D Pipeline

TA	Product	indication	Development					
			Discovery	Preclinical	Phase1	Phase2	Phase3	Launch
Orphan	Delyba Tab	Multi-drug resistant tuberculosis						
	Iclusig Tab	CML, Ph+ ALL						
New drug	OPB-111077	Cancer						
	OPS-2071	Intestinal infection						
	OCV-501	Cancer						
	ASC-01	Schizophrenia						
	SGL-110-04,06,07,12	AML						
	TEV-48125	Episodic migraine, Chronic migraine						
	Rexulti	Schizophrenia, Pediatric						
	Abilify Maintena Inj	Schizophrenia						
	Samsca Tab	Hyponatremia, ADPKD						
	Pletaal SR Cap	Cerebral infarction						
Incrementally Modified Drug	Abilify OD Tab	Schizophrenia						
	Mucosta SR Tab	Gastritis						
Medical Device	Paradise	Resistant hypertension						



For the Best Global Pharmaceutical Company

Korea United Pharm, Inc.

www.kup.co.kr

CEO
DUK YOUNG KANG

Location
Seoul, Gangnam-gu, Nonhy-eon-ro 121street 22

Specialty
Incrementally Modified
Drugs for
1. Antithrombotic
2. Gastrointestinal
3. Respiratory disease

Tel / Fax / E-mail
T. 82-2-512-9981
F. 82-2-548-4599
E. webmaster@kup.co.kr

Since its establishment in 1987, Korea United Pharm has continued to develop various products through prestigious R&D investment. Korea United Pharm has been nominated as one of the "Asia's 200 Best under a Billion" by Forbes for two consecutive years. It has established several overseas branches and corporations to make inroads into the global market. Also, it is striving to do the best to fulfill social responsibilities through various social contribution activities.

Main Products

Product	Active ingredient	Indication
Clanza CR Tab	Aceclofenac	anti-inflammatory
Clavixin Duo Cap.	Clopidogrel + Aspirin	antithrombotic
Cilostan CR Tab.	Cilostazol	antithrombotic
Gastin CR Tab.	Mosapride	functional dyspepsia
Levotics CR Tab.	Levodropropizine	bronchitis
Unigril CR Tab.	Sarpogrelate HCl	antithrombotic
Fenorics EH Tab.	Fenofibric acid	hyperlipidemia
Kalomin S Tab.	Pelargonium sidoides	bronchitis
Glicetil Syrup	Choline alfoscerate	brain functioning
Omethyl Cutilet Soft Cap.	Omega-3-acids ethyl esters 90	hyperlipidemia

R&D Pipeline

TA	Project	Indication	Category	Discovery	Preclinical	Phase I	Phase II	Phase III	Remarks
Respiratory disease	UI009 UI010	Asthma, COPD							
Metabolic disorders	UI018	Hypertriglyceridemia							
Hematological disease	UI022 UI023	Pheripheral arterial disease							
Respiratory disease	UI026	Acute respiratory disease							
Gastrointestinal disease	UI028	Functional dyspepsia	IMD						
Hematological disease	UI036	Nonvalvularatrial fibrillation							
Gastrointestinal disease	UI058	Gastroesophageal reflux disease							
Metabolic disorders	UI061	Hyperlipidemia							
Inflammatory disease	UI063	Antipyretic							



Kuhnil Pharmaceutical Co., Ltd

www.kuhnil.com/english

Under a vision of being a Global pharmaceutical company contributing to improving quality of life, Kuhnil continues to become an unique research focused global company, through development of new drugs, innovative global biopharmaceuticals, DDS and combinations drug products in an effort to improve quality of life in patients. In 2019, Kuhnil received EU GMP certification of the ROSUMEGA and approved the European final product, and Kuhnil has received sales approval of Circadin. And Kuhnil will be lunced a *Daptomycin*.

Main Products

Field	Product	Content	Major Export Country
Cardio Vascular	Omacor Cap	Omega-3-acid ethyl esters	
	Rosumega Cap	Omega-3-acid ethyl esters, Rosuvastatin	Italy, Mongolia
	Experid Pow	Deferasirox	
Central Nervous system	Circadin Tab	Melatonin	
Respiratory	Pulmican Respule	Budesonide micronized	
	Formerol Dry syr.	Formoterol fumarate	
Musculoskeletal Disorders	Lodine kuhnil Cap/Tab /SR Tab	Etodolac Micronized	
Gastrointestinal	Wellcon Tab.	Calcium polycarbophil	
	Bioflor 250 Pow	Saccharomyces boulardii	
	RasB Tab, RasBD Tab	Potassium bismuth citrate, Panitidine hydrochloride, Sucralfate hydrate	
Infectious Disease	Amocla Duo Tab/Syr/inj	Amoxicillin, Potassium clavulanate	

R&D Pipeline

Product	Indication	Research	Preclinical	Phase I / PK	Phase I	Phase I	Launch
KI 1101	Hyperlipidemia						
KI 1102	Hyperlipidemia						
KI 1107	Hyperlipidemia						Market
KI 1114	Hyperlipidemia						Under registration
KI 3101	Hyperlipidemia						Market
KI 3106	Hyperlipidemia						
KI 1120	Female Hypoactive Sexual Desire Disorder						
KI 1121	Hyperlipidemia						
KI 1122	Hyperlipidemia						
KI 1123	Obesity						
KI 1128	Female Hypoactive Sexual Desire Disorder						
KI 1129	Dietary disorders						
KI 1130	NASH						
KI 3110	Intestinal disorders						Under registration
KI 3117	chronic renal failure, Osteoporosis						
KI 1115	Anticoagulant						Market

CEO
Kim Young Joong

Location
OhSong B/D, 14, Jeongdong-gil, Jung-gu, Seoul, Korea, 100-120

Specialty
1. New drug
2. Innovative global biopharmaceuticals
3. DDS pharmaceuticals

Tel / Fax / E-mail
T. 82-2-714-0091
F. 82-2-719-0493
E. kuhnil@kuhnil.com



LG Chem, Ltd

CEO
Hak Cheol Shin

Location
LG Twin Towers, 128, Yeoui-
daero, Yeongdeungpo-gu,
Seoul, South Korea

Specialty
Small molecules/biologics-
based new medicine in oncol-
ogy and immunology, Small
molecules/biologics-based
new medicine for diabetes and
metabolic disease, Vaccine

Tel / Fax / E-mail
T. 82-2-3773-1114
F. 82-2-3773-7813
E. webmaster@kup.co.kr

Based on our superior biotechnology and R&D capabilities accumulated since 1980s, we have been successful in developing a variety of original products including Korea's first growth hormone for children, new drugs for diabetes, etc. We are actively moving beyond the domestic market into overseas markets, and with continued investment and R&D reinforcement, we are expanding the pipeline for new drug development and pushing to become a global pharmaceutical corporation.

Main Products

Products	Description
Zemiglo®/ Zemimet®	The optimized DPP-4 inhibitor having potent efficacy, reliable safety and better compliance benefits/Once daily DPP-IV inhibitor and Metformin SR combination product
Eucept®	The first biosimilar of Etanercept ever developed by LG Chem.
Eutropin®	The right choice for managing short stature recombinant human growth hormone with proven efficacy and safety since 1993
Eupenta®	Combined Diphtheria, Tetanus, whole cell Pertussis, Hepatitis B and Haemophilus influenza typeB. Eupenta can prevent five different childhood disease with a single injection
YVOIRE®	Cross-linked sodium hyaluronate made by microbial fermentation for tissue augmentation and wrinkle correction

R&D Pipeline

Field	Projects	Indication	Discovery	Preclinical	Clinical Trial		
					Phase I	Phase II	Phase III
Vaccine	LR19114	DTP/HepB/Hib/IPV prevention				●	
	LR19113	Poliomyelitis prevention					●
Biologics	LBAL	Autoimmune disease					●
	CUE101	HNSCC			●		
	PDC-lung-101	NSCLC			●		
	LR19156 (Undisclosed)	Obesity		●			
	Stem Cell therapy		●				
	LR19129 (CUE-102/103)	Cancer	●				
Chemicals	DPP4-i + SGLT2	Diabetes					●
	S1P1	Ulcerative colitis				●	
	Xanthine Oxidase	Gout				●	
	LR19021(MC4R)	Obesity		●			
	LR19123 (GPR120)	Diabetes		●			
	LR19018 (Undisclosed)	NASH		●			
	LR19024 (Undisclosed)	OA		●			
	LR19XXX (Undisclosed)	Cancer		●			
	LR19XXX (Undisclosed)	Cancer		●			



Medytox Inc.

As the first botulinum toxin product developer in Korea, we feel pride and responsibility for this industry. Which is why we pursue to improve the transparency and the competitiveness of Korea's biopharmaceutical businesses by implementing of more scientific guidelines for industry practice.

Aiming to become a top global biopharmaceutical company. We plan to expand into the leading pharmaceutical markets and emerging markets. Ceaselessly conducting new research to introduce a new type of botulinum toxin product to the world market.

Main Products



Product	Ingredient	Characteristic
Neuronox®	Clostridium botulinum toxin type A (Hall strain)	<ul style="list-style-type: none"> - Representative brand of Medytox Inc. which is registered in 33 countries. - Neuronox® has ranked No.1 selling product in Korean market, and also in Japan, Thailand.
Innotox®	Clostridium botulinum toxin type A (Hall strain)	<ul style="list-style-type: none"> - The world's first liquid type botulinum toxin type A product. - Excluded the dilution process in using botulinum toxin product improving convenience of treatment and accuracy of dose. - Enhanced safety from excluding animal derivatives and HSA from the final product.
Coretox®	Clostridium botulinum toxin type A (150kDa) (Hall strain)	<ul style="list-style-type: none"> - An advanced new botulinum toxin type A product contains pure neurotoxin, excluding all non-toxin proteins from its ingredients. - Prevents users from gaining immunity by antibody formation which wear down the effects of botulinum toxin. - Enhanced safety from excluding animal derivatives and HSA from the final product.

R&D Pipeline

Division	Code	Indication	Stage
Biodrug	Neuronox®	Benign Masseteric Hypertrophy, Overactive Bladder, Migraine, Glabellar Line(US, EU, China, Taiwan, Russia), Lateral Canthal Line(US, EU), Blepharospasm(China)	Approved + clinical
	Innotox®	Aesthetic and Treatment (US, EU)	Approved + Clinical
	Coretox®	Upperlimb Spasticity	Approved + Clinical
	MT912	Macular Degeneration	Preclinical
	MT927	Immune Disorder	Discovery
	MT971	Inflammatory Bowel Disease	Discovery
	MT981	Solid cancers	Discovery
Synthetic Drugs	MT921	Fat Reduction	Clinical

CEO
Jung Hyun Ho

Location
78, Gangni 1-gil, Ochang-eup,
Cheongwon-gu, Cheongju-si,
Chungcheongbuk-do, Republic
of Korea

Specialty
Botulinum toxin products,
Medical aesthetics, Bio-phar-
maceuticals

Tel / Fax / E-mail
T. 82-2-6901-5880
F. 82-2-3476-8372



Pharam Research Products

CEO
Ki-Seock Kang, Thin-Kyu Kim

Location
77-19, Gwahakdanji-ro, Gang-
neung-si, Gangwon-do, Korea

Specialty
1. Regenerative and immuno-
stimulative medicine
2. Advanced medicine to im-
prove QOL(Quality of life)

Tel / Fax / E-mail
T. 82-31-8039-1500
F. 82-31-8039-1501

PharmaResearchProducts has been researching and developing healthcare products for anti-aging and improving Quality of Life. In 2007, PharmaResearchProducts stood up as a leading regenerative medicine company by developing endogenous repair stimulator PDRN®. Moreover, PharmaResearchProducts diversified the product pipelines for regenerative medicine from on license-in, co-developments to strategic investments. PharmaResearch Products is promoting market expansion in both domestic and global.

Main Products



Category	Product name	Use
Drug	Re-an eye drop	Cornea and conjunctiva regenerative eye drop
	Rejuvenex Injcetion	Wound healing and tissue regenerative injection
Medical Device	Rejuran	New Regenerative Filler (Healer) for Satisfying both skin regeneration and filler effect
	Conjuran	Intra-articular injection for Cartilage regenerative osteoarthritis treatment

R&D Pipeline

Project	2019	2020	2021	2022
Tendinopathy		IND	Clinical Study (Phase 3)	Approval
Atopy medicines		IND	Clinical Study	Approval
Dry eye syndromes	Pre-review	Approval		
PXL01(Global)	IND		Clinical study (Phase 3)	Approval in Europe
PXL01(Domestic)		IND	Clinical study	Approval
LL-37	Clinical study (Phase 2)		Licessing out	
PDRN New Formulation	Non-Clinical Study	IND	Clinical Study	Clinical Study (Phase 3)
Zadaxin New Formulation	Non-Clinical Study	IND	Clinical Study (Phase 1)	Clinical Study (Phase 2)



Pharmicell Co., Ltd.

www.pharmicell.com/eng

Pharmicell Co., Ltd. is a biopharmaceutical company that developed the world's first stem cell therapy (Hearticellgram-AMI) in 2011. The company's business area divided into two sectors as below in detail.

First, in the bio business sector, stem cell R&D for curing obstinate disease and improving human health. Second, the biochemical division develops and produces Raw Material Pharmaceutical Intermediates.


Pharmicell Co., Ltd. will do its best to grow into a respected company for curing obstinate disease and improving human health.

Main Products



Product (Ingredient/Formulation)	Use	Remarks
Hearticellgram-AMI (Autologous Bone Marrow-Derived Mesenchymal Stem Cell)	Acute Myocardial Infarction	Launched
Cellgram-LC (Autologous Bone Marrow-Derived Mesenchymal Stem Cell)	Alcoholic Liver cirrhosis	Developing (Clinical Trial, Phase II completed)
Cellgram-ED (Autologous Bone Marrow-Derived Mesenchymal Stem Cell)	Erectile Dysfunction	Developing (Clinical Trial, Phase I completed)
Cellgram-DC-OC (Prostate Cancer. Ag pulsed Autologous Dendritic Cell)	AnticancerImmuncell Therapeutic Vaccine for Prostate Cancer.	Developing (Clinical Trails)
Cellgram-DC-OC (Ovarian Cancer Ag pulsed Autologous Dendritic Cell)	AnticancerImmuncell Therapeutic Vaccine for Ovarian Cancer.	Developing (Clinical Trails)

R&D Pipeline



CEO
Kim, Hyun Soo

Location
7th floor, Ssangbong Building,
874 Unju-ro, Gangnam-gu,
Seoul-si

Specialty
1. Stem Cell Therapeutics
2. Next Generation Dendritic
Cell Therapeutic Vaccines
3. Raw Material Pharmaceutical
Intermediates

Tel / Fax / E-mail
T. 82-2-3496-0114
F. 82-2-3496-0159
E. pmc@pharmicell.com



FOR THE HEALTHY LIFE & FRUITFUL FUTURE

Samjin Pharmaceutical Co., Ltd.

www.samjinpharm.co.kr/front/en/main/index.asp

CEO
Hong Soon Jang, Yong Ju Choi

Location
121, Wausan-ro, Mapo-gu,
Seoul 04054 Rep. of Korea

Specialty
Manufacture, Marketing and
Distribution of Pharmaceutical
Product (FDF and API)

Tel / Fax / E-mail
T. 82-2-3140-0700
F. 82-2-392-5312

Samjin is a pharmaceutical company striving to produce novel therapeutics with relentless efforts. Since 1968, Samjin has developed steady sellers including antithrombotics, antihyperlipidemics, and NSAIDs, and has been developing novel therapeutics to address high unmet medical needs in the field of ophthalmology, oncology, fibrosis, and neurology. Samjin has established strategic partnerships with 20 profit/non-profit organizations to accelerate innovative drug development and is actively seeking for global partnerships via open innovation.

Main Products

Category	Products	Indication	WWS
FDF	PlatelessTablet (Clopidogrelbisulfate)	Antithrombotic	
	Geworin Tablet (Acetaminophen, etc)	NSAIDs	Philippine, Uzbekistan
	Neustatin-R Tablet (Rosuvastatin calcium)	Antihyperlipidemia	Hongkong, Iraq
	Hanomyacin Injection (Vancomycin hydrochloride)	Antibiotics	Philippine, Dominica Rep., Vietnam
	Neurocava PG Capsule (Pregabalin)	Anticonvulsants	Philippine, Ecuador, Iraq
	Nemeol Tablet (Esomeprazole)	Proton Pump Inhibitors	Hongkong
API	Clopidogrel Bisulfate (Form I & Form II)	Antithrombotic	Indonesia, Egypt
	Rosuvastatin calcium	Antihyperlipidemia	Indonesia
	Apixaban	Anticoagulants	

R&D Pipeline

	Code	Indication	Development Stage	Route of Administration
NCE	SA001 (Rebamide mofetil)	Dry eye syndrome, Sjogren syndrome	Clinical Phase II	Oral
	SJP1803/1804 (NOX inhibitor, APX-1004F)	Macular degeneration	Preclinical	Eye drop, Implant for long-term delivery
	SJP1601 (pan-RAF inhibitor)	Cancer	Preclinical	Oral
	SJP1602 (FAK/Pyk2 dual inhibitor)	Cancer (TNBC)	Preclinical	Oral
	SJP1604 (APTA-DC, APTA-16)	Cancer (Resistant AML/MDS)	Preclinical	Injection
	SJP1901	Cancer, Fibrosis	Biological Testing	-
	SJP1902	Cancer immunotherapy	Biological Testing	-
	SJP1801	Alzheimer's disease, Parkinson's disease	Biological Testing	Oral
IMD	SJP003	Diabetes	Clinical	Oral
	SJP006	Anti-viral	Biological testing	Oral



Samyang Biopharmaceuticals Corporation

www.samyangbiopharm.com/eng

Samyang Biopharm is specialized in development of small-molecule drugs, new biologic drugs and virus vaccines and commercialization of DDS-based modified drugs and first generics for cancer treatment. Samyang Biopharm is exporting its oncology products and expands its product portfolio. Samyang's cytotoxic facility obtained GMP certifications from KR, EU, and JP. the new facility is expected to achieve full cGMP operation. Samyang Biopharm USA Inc. in Cambridge concentrates on global new drug development in immune-oncology and rare diseases.

Main Products

FDF	Product	Formulation	Strength	Specifications
Polymeric Micelle	Genoxel [®] PM	Lyophilized Injection	30mg, 100mg/vial	In-house
	Nanoxel [®] M	Lyophilized Injection	20mg, 80mg/vial	In-house
Generics for Solid Tumors	Paclitaxel	Liquid Injection	30mg, 100mg, 150mg, 300mg/vial	USP, EP
	Docetaxel	Liquid Injection	20mg, 80mg, 140mg, 160mg/vial	EP
	Oxaliplatin	Liquid Injection	50mg, 100mg, 200mg/vial	EP, JP
	Gemcitabine	Liquid Injection	200mg, 1g/vial	USP
		Liquid Injection	1g/vial	In-house
	Pemetrexed	Liquid Injection	100mg, 500mg/vial	In-house
		Lyophilized Injection	100mg, 500mg/vial	In-house
Generics for Blood Cancers	Everolimus	Oral Tablet	2.5mg, 5mg, 10mg/pk	In-house
	Azacitidine	Lyophilized Injection	100mg, 150mg/vial	In-house
	Decitabine	Liquid Injection	40mg, 50mg/vial	In-house
	Bortezomib	Lyophilized Injection	2.5mg, 3.5mg/vial	In-house
	Bendamustine	Liquid Injection	25mg, 100mg/vial	USP
Generis for Supportive Care	Lenalidomide	Oral Tablet	2.5mg, 5mg, 10mg, 15mg, 20mg, 25mg/pk	KP
	Palonosetron	Liquid Injection	0.075mg, 0.25mg, 0.4mg/vial	KP
	Zoledronic Acid	Liquid Injection	4mg/vial	KP
Transdermal Drug Delivery System	Diclofenac	Plaster	120mg	BP
	Nicotine	Patch	14mg, 28mg, 42mg	EP
		Gum	2mg	USP
	Fentanyl	Patch	12µg/h, 25µg/h, 50µg/h, 100µg/h	EP
	Rivastigmine	Patch	6mg(4.6mg/24hr), 12mg(9.5mg/24hr)	EP
	Tulobuterol	Patch	0.5mg, 1mg, 2mg	In-house
	Nitroglycerin	Patch	22.4mg(0.2mg/hr)	USP

API	Product	Package	DMF
Cytotoxic APIs	Paclitaxel	Up to 500 g	US DMF, CEP, KDMF
	Docetaxel	Up to 500 g	US DMF, CEP
	Pemetrexed	Up to 500 g	KDMF
	Bortezomib	Up to 500 g	KDMF
	Cabazitaxel	Up to 500 g	-

R&D Pipeline

Country	Technology	Research	Clinical	Registration
Korea	PM	Paclitaxel		
		Docetaxel		
		SYP-1261		
	PNP	SYP-0709		
		SYP-0709S		
	SEMP	SYO-1906		
	FDT	Ramosetron		
	CSDS	Prednisolone		
	SENS	SYP-1758		
		SYP-1765		
		SYP-1914		
	Metabolic Anticancer	SYO-2001		
USA	Monoclonal antibody	SYB-010		
		SYB-020		

CEO
Taeung Eom

Location
6th Floor, 295 Pangyo-ro,
Bundang-gu, Seongnam-si,
Gyeonggi-do, South Korea

Specialty
1. Drug delivery system of anti-cancer drugs based on small molecules, virus and nucleic acid
2. New biologic anticancer drugs and Rare disease drugs
3. Cytotoxic anticancer drugs

Tel / Fax / E-mail
T. 82-2-2157-9111
F. 82-2-2157-9062



신웅제약(영문)

SHIN POONG PHARM.CO.,LTD.

shinpoong.co.kr/en/main/main.php

Shin Poong Pharm is a R&D oriented pharmaceutical company with global presence in over 50 countries. (Main: CV, bone disease and anti-infectives)

We specialize in manufacturing remedy drugs ranging from active ingredients to finished products based on our state-of-the-art manufacturing facilities and QC system. Under the management philosophy of 'For the Health of the People', we are committed to realizing it with top-notch competitiveness through rigorous efforts in R&D and steady reliability from customers.

Main Products



Name	Indication	Phase	Classification
Pyramax® Tablet	Malaria	On Market	NCE
Pyramax® Granule	Malaria (Pediatric formulation)	On Market	NCE
CandeAmlo® Tablet	Hypertension	On Market	IMD/FDC
EzeRosu® Tablet	Hyperlipidemia	On Market	IMD/FDC
Hyal Forte® Injection	Osteoarthritis	On Market	Generic

※ NCE (New Chemical Entity), NME (New Molecular Entity), IMD (Incrementally Modified Drug)

R&D Pipeline

Category	Products	Indication	Stage
NCE	Otaplimastat (SP-8203)	Acute Ischemic Stroke	Phase 2b (Korea) On-going
	SP-8008	Anti-platelet	Phase 1 (Europe) On-going
	SP-8356	Cerebro-cardiovascular diseases	Preclinical (Europe) Completed
	SP5M001	Osteoarthritis (Long-lasting viscosupplement)	Phase 1/2 (Korea) On-going
	SP-8416	Heart failure	Lead optimization On-going

※ NCE (New Chemical Entity)

CEO

Jei Man Ryu

Location

161, Yeoksam-ro, Gangnam-gu, Seoul, 06246, Republic of Korea

Specialty

1. Composition of raw materials and production lines for antibiotics
2. New drugs and first generic drugs
3. Raw Materials

Tel / Fax / E-mail

T. 82-2-2189-3400

F. 82-2-553-2578

E. sptrade@shinpoong.co.kr



SK Chemicals Co., Ltd.

CEO
Kwanghyun Jeon

Location
310, Pangyo-ro, Bundang-gu,
Seongnam-si, Gyeonggi-do,
Korea [13494]

Specialty

1. Arthritis drug (the nation's first natural medicine)
2. Blood circulation improvement drug (natural medicine)
3. Patch formulation arthritis drug (Incrementally modified drug)

Tel / Fax / E-mail
T. 82-2-2008-2149
F. 82-2-2008-2329
E. jeeho.heo@sk.com

Beginning with "Sunpla", the nation's first self-developed drug that opened a new chapter in Korea's synthetic drug business, SK Chemical has since continued to launch new drugs such as "Mvix"(for erectile dysfunction) and "Joins"(the nation's first natural medicine), establishing a sizable product portfolio. In addition, SK Chemical has marketed a variety of drugs including "Trast"(the world's first patch for arthritis), and "Ginexin"(No.1 market share drug for improving blood circulation).

Main Products



Indication	Product	Product type
Arthritis	Joins	Natural Medicine
Erectile Dysfunction	MVIX	Chemical Drug
Blood circulation	Ginexin	Natural Medicine
Anti inflammatory analgesic	Trast Patch	Chemical Drug

R&D Pipeline

TA	Project	indication	Discovery	Preclinical	Phase I	Phase II	Phase III	Remarks
CNS	QDX	Epilepsy						
CNS	SID1606	Parkinson Disease						
CV	SID142	Peripheral arterial disease						



ST PHARM

cGMP compliant ST Pharm is providing top manufacturing services to satisfy our customers' high expectations to use our products in pharmaceutical industry.

As a member of Dong-A Socio Holdings, ST Pharm is proactively investing our manufacturing equipments to provide cutting edge services which are comprehensive and matching to the fast phased global market.

ST Pharm will continually challenge ourselves to prosper as not only a leading pharmaceutical company but also a global chemical company.

Main Products

Category	Products	Customer	Indication/Stage
New Drug APIs	HCV drug	Originator (Global)	HCV/Marketed
	Diabetes drug	Originator (Global)	Diabetes/Marketed
	Antibiotics drug	Originator (Global)	Antibiotics/Marketed
	Gastric Cancer	Originator (Global)	Gastric Cancer / Phase 3
	Mitochondrial DNA Depletion Syndrome	Originator (Global)	MDDs/Phase 3
Pharmaceutical Intermediates	Chiral epoxide	Originator (Global)	HIV/Marketed
	Chloro-(L)-sugar	Originator (Global)	HBV/Marketed
	Nucleoside monomers	US/EP/JP	Various RNA therapeutics/Clinical
APIs	Atorvastatin	Domestic/JP	Hyperlipidemia/Marketed
	Clopidogrel	Domestic	Anticoagulant/Marketed
	d-Cycloserine	Domestic/JP/WHO/ROW	Tuberculosis/Marketed
	Terizidone	S.Africa/Germany/CIS	Tuberculosis/Marketed
	Gadobutrol	Domestic/EU/CIS	MRI contract/Marketed

R&D Pipeline

Category	Project (Indications)	Stage (on going)
New Drug	STP1002 (cancer)	Phase I
	STP0404 (HIV ALLINI)	Phase I
	STP3725 (Anticoagulants)	Preclinical
	NASH	Discovery
	IBD	Discovery
	Influenza	Discovery

CEO
Kyungjin Kim

Location
231, Hyeomnyeok-ro, Siheung-si, Gyeonggi-do, 15086 Korea

Specialty
Oligo APIs and New Drug Development, CMO(New Drug APIs & Intermediates), Generic APIs

Tel / Fax / E-mail
T. 82-2-527-6351
F. 82-2-561-6006
E. ywshin@stpharm.co.kr



CEO
Tae Young Lee

Location
8 Daesagwan-ro 31 gil,
Yongsan-gu, Seoul, Republic
of Korea

Specialty
1. Ophthalmic IMD
2. Contrast media IMD
3. GI IMD

Tel / Fax / E-mail
T. 82-2-798-6601
F. 82-2-798-6608

Established in 1978, Taejoon is one of the leading specialty pharmaceutical companies in ophthalmology, radiology, and GI. With a global presence in the US, Europe, Asia and Africa, Taejoon has been building up company's future growth based on the business strategy by focusing its corporate resources; specialization, global marketing, and R&D innovation. In particular, Taejoon has acquired US and European GMP certifications to secure global competitiveness and maintains state-of-the-art manufacturing facilities.

Main Products

Product (Ingredient/Formulation)	Use	Exporting Countries	Remarks
Cyporin N Eye drop 0.05% (Cyclosporin)	Dry eye		Launched
Xalost-S Ophthalmic Solution (Latanoprost)	Glaucoma		Launched
Xalostplus Ophthalmic Solution (Latanoprost, Timolol maleate)	Glaucoma	EU, Hong Kong	Launched
Xalost Ophthalmic Solution (Latanoprost)	Glaucoma	EU, China, Nigeria	Launched
Gadobirx Pre-filled Syringe Injection (Gadobutrol)	Contrast enhancement of cranial and spinal MRI		Launched
Iobrix INJ 350 (Iohexol)	Contrast enhancement	Thailand, Philippines	Launched
CleanViewAL Powder (Polyethylene glycol3350)	Bowel cleansing		Launched

R&D Pipeline

Category	Project	Indication	Development process					
			Discovery	Preclinical	Phase I	Phase II	Phase III	Launch
IMD	Undecided	Eye disease						
IMD	Undecided	Eye disease						
IMD	Undecided	Eye disease						
IMD	Undecided	Gastrointestinal disease						
IMD	Undecided	Gastrointestinal disease						



A World Leader in Cell Therapy & Advanced Regenerative Medicine





Tego Science is a Seoul-based biopharmaceutical company specializing in regenerative skin cell therapy for wound healing. Tego's chief strengths have been leading-edge technologies in cell culture, skin-graft manufacturing and cryopreservation. It is now evolving into wider regenerative medicine areas involving musculo-skeletal, ophtalmological and dermatological targets, with plans for overseas expansion. Tego Science has been listed in KOSDAQ since 2014.

Main Products



Product(Ingredient/Formulation)	Use	Exporting Countries(E)	Remark
Holoderm® (Autologous Keratinocytes)	3rd degree burn		Launched
Kaloderm® (Allogenic Keratinocytes)	Deep 2rd degree burn, Diabetic Foot Ulcer	Mongolia, Indonesia	Launched
Rosmir® (Autologous Fibroblasts)	Wrinkles	Vietnam	Launched
Neoderm® (3D Human Skin)	Replacing animal testing	Japan	Launched

R&D Pipeline

Project / Cell & Protein therapy	Indications	Discovery	Pre-Clinical	Clinical Trial			NDA
				I	II	III	
TPX-114 / Dermal fibroblasts (auto)	Full-thickness rotator-cuff tear						
TPX-115 / Dermal fibroblasts (allo)	Partial-thickness rotator-cuff tear						
TPX-113 / Keratinocytes (auto/allo)	Oral mucosal defects						
TPX-107 / Mucosal keratinocytes (auto)	Corneal defects	Investigator Initiated Trial					
TPX-109/ Chemokine	Cartilage defects						

* Arrows indicate current progress with MFDS.

CEO
Saewha Jeon

Location
93, Magokjungang 8-ro,
Gangseo-Gu, Seoul 07794,
Korea

Specialty
1. Dermatological cell therapy,
2. Musculo-skeletal cell
therapy
3. Ophtamological cell therapy

Tel / Fax / E-mail
T. 82-2-818-2900
F. 82-2-2107-3173
E. swbaek@tegoscience.com



Great Yuhan, Global Yuhan



eng.yuhan.co.kr

Yuhan Corporation

CEO
Jung Hee Lee

Location
74, Noryangjin-ro, Daebang-
dong, Dongjak-gu, Seoul,
Korea

Specialty

1. Anticancer Chemical New drug
2. Circulatory System Incrementally Modified Drugs

Tel / Fax / E-mail
T. 82-2-828-0181
F. 82-2-828-0300

Yuhan Corporation has increased the R&D investments since 2015. We licensed out KRW 2.5 trillion worth of technology in 2018, 2019 on licensing and the joint R&D for a new therapeutic candidate treating nonalcoholic steatohepatitis (NASH). As our pipelines continue to expand, today they stand at 27 breakthrough therapies and five IMDs. In pursuit of breakthrough therapies, there are 17 ongoing oncology programs, including immunotherapies and next-generation targeted drugs to fight cancer, such as Lazertinib.

Main Products

Products	Ingredients	Indications	Exporting Countries
Pregabalin SR Tablet	Pregabalin	Neuropathic pain	
Duowell Tablet	Telmisartan, Rosuvastatin	Treatment for hypertension and hyperlipidemia	Uzbekistan
Rosuampine Tablet	Amlodipine, Rosuvastatin	Treatment for hypertension and hyperlipidemia	
Rosumet SR Tablet	Metformin SR, Rosuvastatin	Antidiabetic	
Newfactan	Bovine Lung Surfactant	Treatment for respiratory distress syndrome of newborns	Vietnam, Mongolia, Bolivia
Yucla Tablet	Amoxicillin, Clavulanate Potassium	Antibiotics	
Almagate Suspension	Almagate	Antiacidic functions	
Antiplamine S Lotion	Methyl Salicylate, L-menthol	Anti-inflammatory agent	Vietnam, Malaysia
Willoge Double Action Suspension	Sodium alginate, Calcium carbonate, Sodium bicarbonate	Alleviation of heartburn and indigest	
Nazacare Nasal Spray Solution	Mometasone Furoate	Nasal symptoms of allergic rhinitis, Nasal polyps, Acute rhinosinusitis	

R&D Pipeline

Category	Name	Indication	Discovery	Preclinical study	Phase 1	Phase 2	Phase 3
NCE	Lazertinib	NSCLC					
	YH12852	POI					
	YHC1102	NASH					
	YHC1108	NASH					
	YHC1116	Gaucher					
	YHC1104	NSCLC					
Biologics	YH14618	Degenerative Disk					
	YH25724	NASH					
	YH24931	Immuno-oncology					
	YHC2121	Immuno-oncology					
	YHC2120	Immuno-oncology					
	YHC2110	Obesity					



Yungjin Pharm. Co., Ltd.

Since its establishment in 1952, YUNGJIN PHARM. CO., LTD. has been a pioneer in the Korean domestic pharmaceutical industry for national economic development and improving public health with the lofty mission of saving humanity from disease and suffering through our medicines. As an affiliate of KT&G Group, YUNGJIN plays a pivotal role in the bio/pharmaceutical business within the group with outstanding drug production and R&D know-how, and has grown into a global pharmaceutical company by developing new products and expanding exports.

Main Products

Product	Ingredient	Exporting Countries	Remarks
CEROCAPENE	Cefcapene Pivoxil	Worldwide	API, tab., fine gran.
CEFDITOREN	Cefditoren Pivoxil	Worldwide	API, tab., fine gran.
CEFMETAZOLE	Cefmetazole Sodium	Worldwide	API, inj.
CEFOTIAM	Cefotiam HCl/HCl+Na2CO3	Worldwide	API
CEFTRIAZONE	Ceftriaxone Sodium	Worldwide	inj.
CEFTAZIDIME	Ceftazidime Hydrate	Asia	inj.
CEFOXETIL	Cefpodoxime Proxetil	Asia	API, tab., DS
CEROFAZIL	Cefprozil Hydrate	Asia	tab., DS
CEFDINIR	Cefdinir Hydrate	Asia	API, tab., fine gran.
LOXOPROFEN	Loxoprofen Sodium	Worldwide	API
CANDESARTAN	Candesartan Cilexetil	Asia	API, tab.
FEBUXOSTAT	Febuxostat	Worldwide	API
LINEZOLIN	Linezolid	Worldwide	tab.
YUNGPENEM	Imipenem, Cilastatin	Worldwide	inj.
BAROSCON DOUBLE ACTION	Sodium alginate, calcium carbonate, sodium bicarbonate	Worldwide	susp.
Pediatric Complete Multivitamin	Multivitamins	Worldwide	syr.

R&D Pipeline

Project Name	Therapeutic Area	Indication	Development Status					
			Research	Nonclinical	Phase I	Phase II	Phase III	Marketed
YPL-001	Respiratory	COPD (Asthma)						
YRA-1909	Immunology	Rheumatoid Arthritis						
KL1333	Metabolic Disorder	Mitochondrial Disease						
YPN-005	Oncology	Cancer						
YPN-006	Oncology	Immuno-oncology						
YPI-005	Other Blood Related	Spinal Stenosis						
YPI-008	Cardiovascular	Hypertension Dyslipidemia						
YPI-009	Gastrointestinal	Gastroesophageal Reflux Disease						
YPI-010	Respiratory	Idiopathic Pulmonary Fibrosis						

CEO
Chae Joon Lee

Location
13, Olympic-ro 35da-gil, Songpa-gu, Seoul, 05510, Korea

Specialty

1. NCE(Targeted cancer therapy, Cancer immunotherapy, Rare disease)
2. IMD & Generic (Cephalosporins, Antipyretic-analgesics & Anti-inflammatory, CNS, Rare disease)
3. API(Cephalosporins, Anti-hypertension, Anti-inflammatory, Analgesic)

Tel / Fax / E-mail
T. 82-2-2041-8200
F. 82-2-2041-8201

Pharmaceutical

AGERA BioTech, INC.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Agera BioTec
○ Representative	Soon Young SHIN
○ Establishment year	2016
○ Specialized Field	Development of EGR1-targeting small-molecule compounds for treatment atopic dermatitis; Development of cosmeceuticals for both skincare and skin health
○ Address	Konkuk University, Life Science Bldg. Annex 314, 120 Neungdong-ro, Gwangjin-gu, Seoul, Republic of Korea
○ Home page	- Homepage: www.agerabiotech.com
○ Enterprise Brief Introduction	An R&D-based bioventure company founded with the motto of modern women's natural health and well-being - Development of total skin care cosmeceuticals using plant extracts of <i>Ageratum houstonianum</i> with excellent moisturizing, whitening, anti-wrinkle, antioxidant, and anti-inflammatory effects - Development of innovative therapeutic pipeline for atopic dermatitis by targeting the transcription factor EGR1
○ Product and Pipeline Introduction	1. Commercial product: "AGERIN" brand for skin health cosmeceuticals - Type: Skin moisturizer/Skin barrier repair (toner, serum, cream, mask pack, lift recharging mask cream), Anti-itch (body cream, spotless) 2. Pipeline: - AB1711 for targeted therapy of Atopic dermatitis (targets transcription factor EGR1 to block the production of inflammatory cytokines and itching factors that cause atopic dermatitis)
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	1. Patent: Active ingredient of <i>A. houstonianum</i> for aquaporin-3 expression (KR/1017843310000), A composition of <i>A. houstonianum</i> for cosmetics (KR/1018153400000), Prevention or treatment of itching and atopic dermatitis (KR/1021077480000), Atopic dermatitis prevention, treatment and improvement composition containing a flavone-resveratrol conjugate compound (KR/1021741940000, PCT/KR2021/001805). 2. Certification: Canadian CNF certification (2018), EU CPNP certification (2019), PETA Cruelty-Free certification 3. Licensing: US trademark registration (2020), Vietnam cosmetics registration (2020;28:449-460) 4. Articles: Moisturizing effect of <i>A. houstonianum</i> extract (Scientific Reports 2017;7:11175), Whitening effect of <i>A. houstonianum</i> extract (J Dermatological Science 2018;91:107), skin barrier repair activity of <i>A. houstonianum</i> (J Food and Drug Analysis, 2020;28:449-460), Anti-wrinkle effect of <i>A. houstonianum</i> (Molecular Biology Reports 2021;48:1-11)


AULBIO

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	AULBIO
○ Representative	Ted An
○ Establishment year	2018y
○ Specialized Field	Drug Delivery Technology for Treatment of Diabetes and Obesity
○ Address	2F, Gyeonggi Small and Medium Business Growth Support Center, Suwon-si, Gyeonggi-do
○ Home page	- Homepage: www.aulbio.com
○ Enterprise Brief Introduction	<p>AULBIO, Ltd. is a research-intensive biotechnology start-up company located in Korea.</p> <p>It is engaged globally in the research/development and commercialization of highly technical and innovatively formulated brand products based on state-of-art drug delivery technology (DDT).</p> <p>Using its proprietary platform technology (Extenna™ Microsphere Drug Delivery Tech.), it is developing long-acting biopharmaceutical products that are designed to reduce the number of dosing frequency significantly, resulting in improving the wellbeing of patients. We want to position ourselves enthusiastically and optimistically as a leading innovator in the global biopharmaceutical market, today and for the future.</p>
○ Product and Pipeline Introduction	<p>1. Drug delivery technology using microspheres</p> <ul style="list-style-type: none"> - By using drugs for diabetes and obesity treatment with proven stability and effectiveness, and a microsphere drug delivery system made of biocompatible polymers, it achieves sustained drug efficacy for one month with a single administration. <p>2. Long-lasting drug treatment for diabetes and obesity</p> <ul style="list-style-type: none"> - AULBIO's diabetes · obesity injections are a new concept treatment that has been drastically reduced the number of administrations compared to the previous one, as the drug lasts for a month with one injection.
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<ul style="list-style-type: none"> - Patents: 1 registration, 3 applications - Investment of Series A : 3M\$ - Investment of Series A bridges : 3.5M\$ - Selection of 『2018 TIPS Program』 - Selection of 『BIG3 Project』 - 2020 Challenge K-Startup “Ministry of Science and Technology Award”

ELI Frontier Corporation

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	ELI Frontier Corporation
○ Representative	Kim Jun hwan
○ Establishment year	18th, November 2019
○ Specialized Field	Health functional food and new drug development with edible insects
○ Address	Songdo0dong, Yeonsu gu, Incheon, Rebpublic of Korea
○ Home page	- Homepage:
○ Enterprise Brief Introduction	<p>ELI Frontier is founded for development of health functional food and new drug with edible insects. ELI Frontier constructed edible insects total web platform “YoutoBugs” to connet insect farm and R&D company developing foods, new drugs, and cosmetics. YoutoBugs is being promoted. ELI Frontier has plans to develop cell-culture meat with cricket muscle cells and to develop drug delivery system with insect chitin.</p>
○ Product and Pipeline Introduction	<p>1. Edible insect platform “YoutoBugs”</p> <ul style="list-style-type: none"> - “YoutoBugs” is deveoped for connection between edible inscets farms and R&D companies for food, new drugs, and cosmetics. This platform can provide both stable sales to farms and cost reduction to companies in early stage. <p>2. Cricket muscle cell-culture meat</p> <ul style="list-style-type: none"> - Edible cricket has high protein, low fat, and high BCAA. Cricket cell-culture meat jercky can be a solution to make up uncomfortable texture of cell-culture meat.
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Patent application : The purification method of Chitin protein from Gryllus bimaculatus

Geneuin-Tech Co., Ltd.

Category	Enterprise Creation																																																																						
○ Corporation (Preliminary Enterprise)	Geneuin-Tech Co., Ltd.																																																																						
○ Representative	Han Eun Yeong																																																																						
○ Establishment year	2015. 03. 04																																																																						
○ Specialized Field	Recombinant virus producing service																																																																						
○ Address	Bldg.H #404, Inje university, 197 inje-ro, Gimhae-si Gyeongsangnam-do																																																																						
○ Home page	- Homepage: www.geneuintech.com																																																																						
○ Enterprise Brief Introduction	<p>Geneuin-Tech is a high-tech bio company that develops gene therapy drugs and was founded with the idea of restoring the original human form by treating genes, which is the fundamental cause of these disease. As the only company in Korea and abroad with 5 types of recombinant virus technology, it has many pipelines and platforms using this core technology.</p> <p>We are developing safe and innovative treatments in the fields of gene therapy, cell therapy, and preventive vaccines, and we hope that co-developments and clinical trials will serve as a pathway for the treatment of children with rare disease in pain.</p>																																																																						
○ Product and Pipeline Introduction	<ul style="list-style-type: none">● Vaccine platform & Cell line platform<ul style="list-style-type: none">• Manufacturing in BSL 2(Biosafety Level 2) facility not in BSL 3.• Rapid vaccine production by inserting a target gene sequence• More efficient antibody production through nasal inhalation• RCA free cell line, it is not pathogenic and not harm the human body.• Solving the problem of anaphylaxis and Zoonosis, a side effect of the vaccine● Gene therapy platform (Inherited retinal dystrophies)<ul style="list-style-type: none">• Gene therapy based on target-oriented AAV• Long-term expression of target genes possible• Cell-specific expression possible• Safe and high-efficiency, high-purify virus manufacturing technology● Cell therapy platform (CAR-T cell therapy)<ul style="list-style-type: none">• A new way of recognizing DR4 (Death receptor 4) cell therapy of CAR-T cell therapy• A dual-acting cell therapy (Cytotoxicity, Apoptosis)• Blocking the problem that tumor cells are converted into resistant tumor cells though mutation																																																																						
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<div>Intellectual property right</div> <table><thead><tr><th>Project name</th><th>Type</th><th>Candidate material</th><th>Indications</th><th>Patent</th></tr></thead><tbody><tr><td>GT513</td><td>Bio New Drug (Gene Medicine)</td><td>Anticancer gene</td><td>Lung cancer</td><td>Geneuin-Tech Registration</td></tr><tr><td>GT515</td><td>Bio New Drug (Preventive vaccine)</td><td>COVID-19</td><td>COVID-19 vaccine</td><td>Geneuin-Tech patent application (US, EU)</td></tr><tr><td>GT516</td><td>Bio New Drug (Target cancer cell therapy)</td><td>CAR-T</td><td>Non-small cell lung cancer</td><td>Geneuin-Tech Register PCT</td></tr><tr><td>GT517</td><td>Bio New Drug (Preventive vaccine)</td><td>AI</td><td>Bird flu vaccine</td><td>Geneuin-Tech Register PCT</td></tr><tr><td>GT518</td><td>Bio New Drug (Preventive vaccine)</td><td>Foot-and-mouth</td><td>Foot-and-mouth disease vaccine</td><td>Patent application</td></tr><tr><td>GT519</td><td>Bio New Drug</td><td>Nerve gene</td><td>Brain disease</td><td>Geneuin-Tech Registration</td></tr><tr><td>GT521 / GT531</td><td>technical transfer</td><td>Artemisia capillaris</td><td>Stomach health</td><td>Geneuin-Tech technical transfer registration</td></tr><tr><td>GT521</td><td>A new drug for natural products</td><td>Artemisia capillaris</td><td>Nonalcoholic hepatitis</td><td>Geneuin-Tech Improve patent</td></tr><tr><td>GT531</td><td>Health functional food / natural medicine Functional raw materials</td><td>Artemisia capillaris</td><td>Stomach health</td><td>Geneuin-Tech Improve patent</td></tr><tr><td>GT532</td><td>Health functional food / natural medicine Functional raw materials</td><td>Saururus chinensis extract</td><td>Antiviral immunity increase</td><td>Geneuin-Tech, Inje University Joint patent registration</td></tr><tr><td>GT541</td><td>Biopharmaceutical</td><td>RCA free Production cell line</td><td>-</td><td>Geneuin-Tech Registration PCT application (US, EU, CH)</td></tr><tr><td>GT551</td><td>Biopharmaceutical</td><td>New compound</td><td>Anti-viral drug</td><td>Patent application</td></tr><tr><td>GT552</td><td>Biopharmaceutical</td><td>Compound</td><td>Anti-viral drug</td><td>Patent application</td></tr></tbody></table>	Project name	Type	Candidate material	Indications	Patent	GT513	Bio New Drug (Gene Medicine)	Anticancer gene	Lung cancer	Geneuin-Tech Registration	GT515	Bio New Drug (Preventive vaccine)	COVID-19	COVID-19 vaccine	Geneuin-Tech patent application (US, EU)	GT516	Bio New Drug (Target cancer cell therapy)	CAR-T	Non-small cell lung cancer	Geneuin-Tech Register PCT	GT517	Bio New Drug (Preventive vaccine)	AI	Bird flu vaccine	Geneuin-Tech Register PCT	GT518	Bio New Drug (Preventive vaccine)	Foot-and-mouth	Foot-and-mouth disease vaccine	Patent application	GT519	Bio New Drug	Nerve gene	Brain disease	Geneuin-Tech Registration	GT521 / GT531	technical transfer	Artemisia capillaris	Stomach health	Geneuin-Tech technical transfer registration	GT521	A new drug for natural products	Artemisia capillaris	Nonalcoholic hepatitis	Geneuin-Tech Improve patent	GT531	Health functional food / natural medicine Functional raw materials	Artemisia capillaris	Stomach health	Geneuin-Tech Improve patent	GT532	Health functional food / natural medicine Functional raw materials	Saururus chinensis extract	Antiviral immunity increase	Geneuin-Tech, Inje University Joint patent registration	GT541	Biopharmaceutical	RCA free Production cell line	-	Geneuin-Tech Registration PCT application (US, EU, CH)	GT551	Biopharmaceutical	New compound	Anti-viral drug	Patent application	GT552	Biopharmaceutical	Compound	Anti-viral drug	Patent application
Project name	Type	Candidate material	Indications	Patent																																																																			
GT513	Bio New Drug (Gene Medicine)	Anticancer gene	Lung cancer	Geneuin-Tech Registration																																																																			
GT515	Bio New Drug (Preventive vaccine)	COVID-19	COVID-19 vaccine	Geneuin-Tech patent application (US, EU)																																																																			
GT516	Bio New Drug (Target cancer cell therapy)	CAR-T	Non-small cell lung cancer	Geneuin-Tech Register PCT																																																																			
GT517	Bio New Drug (Preventive vaccine)	AI	Bird flu vaccine	Geneuin-Tech Register PCT																																																																			
GT518	Bio New Drug (Preventive vaccine)	Foot-and-mouth	Foot-and-mouth disease vaccine	Patent application																																																																			
GT519	Bio New Drug	Nerve gene	Brain disease	Geneuin-Tech Registration																																																																			
GT521 / GT531	technical transfer	Artemisia capillaris	Stomach health	Geneuin-Tech technical transfer registration																																																																			
GT521	A new drug for natural products	Artemisia capillaris	Nonalcoholic hepatitis	Geneuin-Tech Improve patent																																																																			
GT531	Health functional food / natural medicine Functional raw materials	Artemisia capillaris	Stomach health	Geneuin-Tech Improve patent																																																																			
GT532	Health functional food / natural medicine Functional raw materials	Saururus chinensis extract	Antiviral immunity increase	Geneuin-Tech, Inje University Joint patent registration																																																																			
GT541	Biopharmaceutical	RCA free Production cell line	-	Geneuin-Tech Registration PCT application (US, EU, CH)																																																																			
GT551	Biopharmaceutical	New compound	Anti-viral drug	Patent application																																																																			
GT552	Biopharmaceutical	Compound	Anti-viral drug	Patent application																																																																			

HEDGEHOG, Inc.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	HEDGEHOG, Inc.
○ Representative	Sang Cheul Oh
○ Establishment year	Nov 2018
○ Specialized Field	Development of Antibody/Synthetic/Natural Anti-cancer Drugs
○ Address	#204, 2F, 226, Gamasan-ro, Guro-gu, Seoul, Republic of Korea
○ Home page	- Homepage: www.hedgehogtec.com
○ Enterprise Brief Introduction	We are developing a new anticancer drug that targets Hedgehog, a gene that is overexpressed in various cancers and is involved in embryonic development and cell growth.
○ Product and Pipeline Introduction	<p>1. HH101: Mouse-derived fully humanized SMO antibody.</p> <p>2. HH102: Anti-Human EPHB3 Single Clone Antibody. EPHB3 single-clone human antibodies are being developed as first in class antibody treatments that competitively inhibit the binding of EPHB3 and the ligand Eprn.</p> <p>3. HH103: Anti-Human ETAR Single Clone Antibody. We are developing a new anti-cancer drug that competitively inhibits the combination of ETAR and ligand Endothelin.</p> <p>4. HH201: It is a low-molecular compound treatment that inhibits the role of GLI transcription factors and is being developed as a best in class treatment that has a differential effect from the existing treatment.</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>(Patent) 2 applications in Korea 3 registrations in Korea 3 applications in Overseas</p> <p>(Certification) Venture company confirmation_2020.12.28.</p> <p>(Licensing) Establishment of research institute.</p>





Inventera Pharmaceutical Inc.

Corporation	Inventera Pharmaceutical Inc.
○ Representative	Tae-Hyun Shin
○ Establishment year	2018
○ Specialized Field	MRI contrast agent
○ Address	SB Plaza 3F A1, 194-25, Osong Saengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do
○ Home page	- http://www.inventerapharm.com
○ Enterprise Brief Introduction	<p>- Inventera Pharmaceuticals Inc. is a bio tech company developing groundbreaking technologies, ranging from new materials and high-value therapeutics and diagnostics.</p> <p>- Established in November 2018, we received one of the most prestigious gov'n't research grants (TIPS program) from Ministry of SMEs and Startups (December, 2018). In 2020, we successfully raised series A fund (50 억won) from venture capitals and pharmaceutical companies.</p> <p>- We are now focusing on development of first-/best-in-class T1-MRI contrast agents. Our contrast agent is free from toxic gadolinium and can provide ~100 micrometer high-spatial-resolution MRI images.</p> <p>Key indications of our contrast agents are (i) cerebrocardiovascular and (ii) musculoskeletal, which are the largest segments of contrast agents market.</p> <p>- Musculoskeletal contrast agents (code name: INV-002) are approved for clinical phase I/IIa studies by the Ministry of Food and Drug Safety. Cerebrocardiovascular contrast agents (code name: INV-001) is in preclinical stage.</p>
○ Product and Pipeline Introduction	<p style="text-align: center;">“Renal clearable high-resolution T1-MRI contrast agents”</p> <p>1) Iron-based T1-MRI contrast agents (gadolinium-free)</p> <p>2) Long circulating pharmacokinetics enabling high-resolution scanning</p> <p>3) Thorough renal excretion capability</p> <hr/> <p>1) Code name INV-002</p> <p>-Indication: Musculoskeletal system</p> <p>-Development stage: Clinical phase 1/2a (IND approved by the Ministry of Food and Drug Safety)</p> <p>2) Code name INV-001</p> <p>-Indication: Cerebrovascular</p> <p>-Development stage: Preclinical</p> <p>3) Code name: INV-003R</p> <p>-Indication: Cerebrovascular (for research)</p> <p>-Development stage: Completed (currently used as research purpose contrast agents by researchers)</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Patent: Republic of Korea No. 10-1991912 / Japan 6309542 Applied in the US, China, and Europe

KCNB Bio

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	KCNB Bio
○ Representative	Ku Yeon Kil, Hong Soon Young
○ Establishment year	25 th may, 2020
○ Specialized Field	Cannabis pharmaceuticals - Development, raw materials and product including Cannabidiol (CBD)
○ Address	#301 New B/D, 5, Saneopdanji 2-gil, Pungsan-eup, Andong-si, Gyeongsangbuk-do, 36618, Rep. of KOREA
○ Home page	- Homepage: http://www.cnbbio.co.kr/
○ Enterprise Brief Introduction	<ul style="list-style-type: none"> - Expansion of cannabis pharmaceutical market - R&D fund / R&D center and factory - Patent, manufacture and pipeline
○ Product and Pipeline Introduction	<ol style="list-style-type: none"> 1. Cannabidiol(CBD) raw material & CBD oil <ul style="list-style-type: none"> - Development, Cooperative work, Pipeline - Generic CBD oil 2. Cannabigerol(CBG) 3. Cannabinoids
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Patent / R&D center, Manufacture facilities under preparations

NANOFAENTECH

Category	Enterprise Creation																																												
○ Corporation	NANOFAENTECH Co., Ltd.																																												
○ Representative	Jong-Young Kwak																																												
○ Establishment year	2018																																												
○ Specialized Field	High-performance nanofiber for 3D cell culture																																												
○ Address	88 Somang-gil, Juchon-myeon, Gimhae-si, Gyeongsangnam-do, Medical Practical Center 604																																												
○ Home page	- Homepage: www.nanofaentech.com																																												
○ Enterprise Brief Introduction	<div><div><div><ul style="list-style-type: none">• CEO, Jong-Young Kwak• Professor, Department of Pharmacology, Ajou Univ. School of Medicine• Director, 3D Immune System Imaging Core Center• Member of Russian Academy of Science• Post Doc, Emory Univ. School of Medicine• M.D & Ph.D., Busan National Univ.</div><div></div></div><div><div><div>■ Management, Organization</div><div>■ Business Area<ul style="list-style-type: none">- Three-dimensional cell culture membrane- 3D cell culture systems- Culture plates for 3D cell culture systems</div><div>■ Business contents<ul style="list-style-type: none">- Functional biomaterial-blended polyvinyl alcohol (PVA) nanofibers to be developed as membrane for 3D cell culture- Hepatocyte culture system- Development and sale of primary hepatocyte and epithelial cell culture system</div></div><div><div>■ Research and Development Goals<ul style="list-style-type: none">- Utilize technology to produce products that respond to consumer markets such as nanofiber sheets and well plates- Development of various models for 3D cell culture using PVA nanofiber- Implementation of drug testing services by establishing 3D incubation conditions from the development of nanofiber supports</div><div></div></div></div></div>																																												
○ Product and Pipeline Introduction	<div><div><div>■ Core Technology<ul style="list-style-type: none">- Water-stable polyvinyl alcohol nanofiber- Transparent nanofiber membrane- Cell-adhesive polyvinyl alcohol nanofiber membrane</div><div></div></div></div>																																												
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<div><div><div>■ A Key Patent<table><thead><tr><th>The name of an invention</th><th>Inventor</th><th>Appl. No.</th><th>Registration date</th><th>Status</th><th>Country of possession</th></tr></thead><tbody><tr><td rowspan="3">Method of Manufacturing a Polyvinyl Alcohol Nanofiber Structure for Cell Culture</td><td rowspan="3">Jong-Young Kwak</td><td>10-1665918</td><td>2016.10.06</td><td>Registered</td><td>Republic of Korea</td></tr><tr><td>16319148</td><td>2019.01.18</td><td>Filed</td><td>U.S</td></tr><tr><td>PCT/KR2017/000393</td><td>2017.01.12</td><td>Filed</td><td>PCT</td></tr><tr><td rowspan="2">Method for manufacturing polyvinyl alcohol nanofiber membrane enhancing cell specific adhesion</td><td rowspan="2">Jong-Young Kwak</td><td>10-2176892</td><td>2020.11.04</td><td>Registered</td><td>Republic of Korea</td></tr><tr><td>16803957</td><td>2020.02.27</td><td>Filed</td><td>U.S</td></tr><tr><td rowspan="3">Nanofiber-based Long-term Primary Hepatocyte Three-dimensional Culture System</td><td rowspan="3">Jong-Young Kwak</td><td>10-2062465</td><td>2019.12.27</td><td>Registered</td><td>Republic of Korea</td></tr><tr><td>16649986</td><td>2020.07.30</td><td>Filed</td><td>U.S</td></tr><tr><td>PCT/KR2018/011215</td><td>2018.09.21</td><td>Filed</td><td>PCT</td></tr></tbody></table></div><div>■ Other Authentication<ul style="list-style-type: none">• KIBO, Certification of venture companies('20.11.)• KIBO, Selection of U-TECH Valley companies('20.11.)• Approval for the entrance of GMP facilities('20.11.)</div></div></div>	The name of an invention	Inventor	Appl. No.	Registration date	Status	Country of possession	Method of Manufacturing a Polyvinyl Alcohol Nanofiber Structure for Cell Culture	Jong-Young Kwak	10-1665918	2016.10.06	Registered	Republic of Korea	16319148	2019.01.18	Filed	U.S	PCT/KR2017/000393	2017.01.12	Filed	PCT	Method for manufacturing polyvinyl alcohol nanofiber membrane enhancing cell specific adhesion	Jong-Young Kwak	10-2176892	2020.11.04	Registered	Republic of Korea	16803957	2020.02.27	Filed	U.S	Nanofiber-based Long-term Primary Hepatocyte Three-dimensional Culture System	Jong-Young Kwak	10-2062465	2019.12.27	Registered	Republic of Korea	16649986	2020.07.30	Filed	U.S	PCT/KR2018/011215	2018.09.21	Filed	PCT
The name of an invention	Inventor	Appl. No.	Registration date	Status	Country of possession																																								
Method of Manufacturing a Polyvinyl Alcohol Nanofiber Structure for Cell Culture	Jong-Young Kwak	10-1665918	2016.10.06	Registered	Republic of Korea																																								
		16319148	2019.01.18	Filed	U.S																																								
		PCT/KR2017/000393	2017.01.12	Filed	PCT																																								
Method for manufacturing polyvinyl alcohol nanofiber membrane enhancing cell specific adhesion	Jong-Young Kwak	10-2176892	2020.11.04	Registered	Republic of Korea																																								
		16803957	2020.02.27	Filed	U.S																																								
Nanofiber-based Long-term Primary Hepatocyte Three-dimensional Culture System	Jong-Young Kwak	10-2062465	2019.12.27	Registered	Republic of Korea																																								
		16649986	2020.07.30	Filed	U.S																																								
		PCT/KR2018/011215	2018.09.21	Filed	PCT																																								

NineBiopharm Co., Ltd.

Category	Enterprise Creation																	
○ Corporation (Preliminary Enterprise)	NineBiopharm Co., Ltd.																	
○ Representative	Jae-Duck Ryoo																	
○ Establishment year	03/02/2015																	
○ Specialized Field	Bio-New Material Development, Peptidomimetic Material Development																	
○ Address	125, Osongsangmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea																	
○ Home page	- Homepage:																	
○ Enterprise Brief Introduction	NineBiopharm Co., Ltd. is a company that focuses on identifying noble biomaterials with its proprietary ARisT (Advanced Remodeling in silico Technology), a remodeling platform that can maximize targeting, sustainability, activity, and commercialization of materials based on in-silico technology designed to increase efficiency and reduce cost significantly vs. the conventional drug development platform HTS(High-throughput screening).																	
○ Product and Pipeline Introduction	<table border="1"> <tr> <td rowspan="3">- Medical devices</td><td>Filler(injectable dermal fillers)</td></tr> <tr> <td>Wound dressing</td></tr> <tr> <td>Body filler(Lipolytic filler)</td></tr> <tr> <td rowspan="7">- Medicines</td><td>CPP(Cell Penetrating Peptide)</td></tr> <tr> <td>Osteoarthritis medication</td></tr> <tr> <td>Obesity treatment</td></tr> <tr> <td>Acne treatment</td></tr> <tr> <td>Anti-microbial cream</td></tr> <tr> <td>Psoriasis treatment, Atopic dermatitis</td></tr> <tr> <td>Hair loss prevention and hair regrowth</td></tr> <tr> <td rowspan="4">- Cosmetics</td><td>Anti-cancer drug</td></tr> <tr> <td>Anti-wrinkle/whitening</td></tr> <tr> <td>Anti-pollution</td></tr> <tr> <td>Acne cream</td></tr> </table>	- Medical devices	Filler(injectable dermal fillers)	Wound dressing	Body filler(Lipolytic filler)	- Medicines	CPP(Cell Penetrating Peptide)	Osteoarthritis medication	Obesity treatment	Acne treatment	Anti-microbial cream	Psoriasis treatment, Atopic dermatitis	Hair loss prevention and hair regrowth	- Cosmetics	Anti-cancer drug	Anti-wrinkle/whitening	Anti-pollution	Acne cream
- Medical devices	Filler(injectable dermal fillers)																	
	Wound dressing																	
	Body filler(Lipolytic filler)																	
- Medicines	CPP(Cell Penetrating Peptide)																	
	Osteoarthritis medication																	
	Obesity treatment																	
	Acne treatment																	
	Anti-microbial cream																	
	Psoriasis treatment, Atopic dermatitis																	
	Hair loss prevention and hair regrowth																	
- Cosmetics	Anti-cancer drug																	
	Anti-wrinkle/whitening																	
	Anti-pollution																	
	Acne cream																	
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<ul style="list-style-type: none"> - 11 patents applied or registered - 2020 R&D fund from Ministry of Health and Welfare's R&D project: KRW 2.1 billion - Series A financing: investment firm KRW 2.5 billion 																	

ONCOCROSS

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Oncocross
○ Representative	Yirang Kim
○ Establishment year	2015
○ Specialized Field	Drug Development using AI platform
○ Address	16F, 11, Seacahng-ro, Mapo-gu, Seoul 04168
○ Home page	- Homepage: www.oncocross.com
○ Enterprise Brief Introduction	Oncocross is an AI drug development company that predicts the interaction between drugs and diseases using AI (Artificial Intelligence) based on gene expression patterns. We started based on a platform technology that searches for a disease that is predicted to have this effect or, on the contrary, searches for a drug that is expected to have an effect on the disease.
○ Product and Pipeline Introduction	<p>RAPTOR AI®: As an AI drug development platform that focuses on screening the optimal indications for drugs, it is possible to derive new indications for new clinical drugs or approved drugs already on the market, or to improve efficacy through concurrent administration. It plays a role in reducing the risk of failure in the new drug development stage and shortening the development period by deriving treatment combinations. We have 17 pipelines that treat liver diseases, cancer, rare diseases, cardiovascular disease, infectious diseases, skin diseases, Central nervous system, and metabolic diseases identified by RAPTOR AI.</p> <p>ONCOFind AI®: Predicts the optimal treatment option and timing to increase the survival rate of cancer patients by quickly and accurately predicting the primary site of primary and unknown metastatic cancer, which accounts for 2-6% of all cancer cases.</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>8 papers related to AI platform and its pipeline</p> <p>Total 28 patents including 8 PCT, 20 domestic patents related AI platform and pipeline</p> <p>Investment of Series A (6 billion won) and Series B (16.5 billion won)</p>

S&K Therapeutics

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	S&K Therapeutics
○ Representative	Choi Sangdun
○ Establishment year	2020
○ Specialized Field	Development of medicines for autoimmune diseases and inflammatory diseases
○ Address	Woncheon-gwan 135, Ajou University, Worldcup-ro 206, Yeongtong-gu, Suwon-si, 16499, Gyeonggi-do
○ Home page	- Homepage: http://www.snktherapeutics.com
○ Enterprise Brief Introduction	- S&K Therapeutics is focusing its core capabilities on developing new small molecule drugs to meet the unmet medical needs, and aims to develop new medicines for systemic lupus erythematosus, rheumatoid arthritis, psoriasis, Alzheimer's and diabetes.
○ Product and Pipeline Introduction	- S&K Therapeutics owns an artificial intelligence-based drug development platform that allows to discover new molecular entities effectively. Furthermore, based on extensive research experience on TLRs (Toll-like receptors), S&K therapeutics possesses new drug development pipelines for autoimmune diseases, inflammatory diseases, and viral diseases.
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Patent Applications: KR10-2020-0160977 (2020.11.26) KR10-2020-0126710 (2020.09.29) KR10-2021-0015425 (2021.02.03)

TiCARos

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	TiCARos
○ Representative	Jaewon Lee
○ Establishment year	2018
○ Specialized Field	Next Generation CAR-T Therapy
○ Address	sungsuAKvalley 1102, 76 Yeonmujaeng-gil, Seongdong-gu, Seoul, Republic of Korea
○ Home page	- Homepage: www.ticaros.com
○ Enterprise Brief Introduction	<p>TiCARos develops matchless CAR-T and cell therapeutics for cancer treatment, by leveraging accumulated experiences and technologies of the immunologists at Seoul National University, College of Medicine. We hope that these efforts will lead to a novel breakthrough in treatment of not only intractable hematologic malignancies but also of advanced solid tumors.</p> <p>We have three platform technologies to overcome the limitations of CAR-T therapy, and we are working on three pipelines to treat blood and solid tumors.</p> <ul style="list-style-type: none"> - Converter CAR: Technology for strengthening immune activities of T cells themselves - CLIP CAR: Technology to improve effectiveness of CAR-T therapy by changing CAR backbone - Switchable CAR molecule: Switchable CAR technology improves the safety of CAR-T treatments
○ Product and Pipeline Introduction	<ul style="list-style-type: none"> • TC011 (CD19 CLIP CAR-T) <ul style="list-style-type: none"> - Targeting Lymphoma - Enhancement of T cell-APC interaction with CAR backbone modification - In-vivo experiments show full tumor regression even in doses that commercial products do not show therapeutic effects. • TC003 (B7H3 antibody applied) <ul style="list-style-type: none"> - Strategies to overcome the heterogeneity of tumor antigens - Targeting solid cancer with self-made antibody - CLIP and Converter technologies will be applied to overcome immune resistance of tumors
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<ul style="list-style-type: none"> • 2014~2017 Converter CAR Patent Registration • 2020 CLIP CAR Patent Application • 2019 Series A,B funding(KRW 8.1 bil)

WellPep Co.,LTD

Category	Enterprise Creation																	
○ Corporation (Preliminary Enterprise)	WellPep Co.,LTD																	
○ Representative	Kweon Yeong Ik, Kim Jong Min																	
○ Establishment year	2018																	
○ Specialized Field	New Peptide Drug and Research/Cosmetic Peptide Material																	
○ Address	Rm 310, instal, 204 Convensia-daero, Yeonsu-gu, Incheon, Republic of Korea																	
○ Home page	- Homepage: www.wellpep.co.kr																	
○ Enterprise Brief Introduction	-The specialized company in the development of bio-friendly new peptide-drug candidates -Unique module-combined peptide synthesis technology with large manufacturing capacity -Experienced a listed KOSDAQ technology special case																	
○ Product and Pipeline Introduction	<div>[Introduction] Development of market-friendly new peptide drug candidates - Development of candidate raw materials for new peptide-derived drugs demanded by customers(Big Pharma) - Planning to expand multiple pipelines with competitive potential (within 1~2/year) - Development of best-in-class and first-in-class materials complying with unmet needs - Strategic goal to licensing out to global big pharma and leading companies</div> <div>[Development stage]</div> <table><tr><td>Technology application</td><td>Development stage</td><td>Detailed description</td></tr><tr><td>Multidrug-resistant antimicrobial peptide drug</td><td>Candidate substance screening (Safety, efficacy study: in vitro)</td><td>Joint study (Incheon Univ/KBSI)</td></tr><tr><td>Alzheimer’s disease Inhibitor</td><td>Candidate substance screening (Safety, efficacy study: in vitro)</td><td>Joint study (Aju Univ.)</td></tr></table>			Technology application	Development stage	Detailed description	Multidrug-resistant antimicrobial peptide drug	Candidate substance screening (Safety, efficacy study: in vitro)	Joint study (Incheon Univ/KBSI)	Alzheimer’s disease Inhibitor	Candidate substance screening (Safety, efficacy study: in vitro)	Joint study (Aju Univ.)						
Technology application	Development stage	Detailed description																
Multidrug-resistant antimicrobial peptide drug	Candidate substance screening (Safety, efficacy study: in vitro)	Joint study (Incheon Univ/KBSI)																
Alzheimer’s disease Inhibitor	Candidate substance screening (Safety, efficacy study: in vitro)	Joint study (Aju Univ.)																
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<div>- 7 Patent application (Applicaction number: PCT/KR2019/013926, 10-2019-0174349, 10-2020-0056056, 10-2020-0086609, 10-2020-0162592, 10-2020-0162593, 10-2020-0175373) - 3 Patent registered (Patent number: 10-1381285, 10-2146006. 10-2177642) - Certified Venture Business and, ISO-9001/14001 - Current Investment attraction status</div> <div>(Unit: KRW 1,000)</div> <table><tr><td>Investment destination</td><td>Amount</td><td>Stock</td></tr><tr><td>SID partners No.2 Angel Fund</td><td>22,500</td><td>13,000</td></tr><tr><td>Big Bang Angels Investment association No.14</td><td>100,000</td><td>59,180</td></tr><tr><td>Incheon Intellectual Property No. 2 Investment association</td><td>100,000</td><td>51,000</td></tr><tr><td>계</td><td>222,500</td><td>123,180</td></tr></table>			Investment destination	Amount	Stock	SID partners No.2 Angel Fund	22,500	13,000	Big Bang Angels Investment association No.14	100,000	59,180	Incheon Intellectual Property No. 2 Investment association	100,000	51,000	계	222,500	123,180
Investment destination	Amount	Stock																
SID partners No.2 Angel Fund	22,500	13,000																
Big Bang Angels Investment association No.14	100,000	59,180																
Incheon Intellectual Property No. 2 Investment association	100,000	51,000																
계	222,500	123,180																

Medical Device

Biot Korea Inc.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Biot Korea Inc.
○ Representative	Yeongjun Chang
○ Establishment year	2017
○ Specialized Field	Medical robot
○ Address	302, 43-26, Cheomdangwagi-ro 208beon-gil, Buk-gu, Gwangju, Republic of Korea
○ Home page	- Homepage: www.biotinc.com
○ Enterprise Brief Introduction	BIOT is a young start-up researching medical robot systems such as RAPIDS Platform, an automated molecular diagnosis system, and Stem Cell Navigator, a medical device platform that enables physical delivery of therapeutic agents. We are commercializing our products with many domestic and foreign researchers and top hospitals for a healthy future for humanity.
○ Product and Pipeline Introduction	<p>1. The world's first medical robot capable of collecting non-face-to-face samples of respiratory viral infections "RAPIDS Platform"</p> <p>- Introduction: The RAPIDS Platform, which makes it possible to collect samples performed face-to-face by medical staff on a non-face-to-face basis, through remote control, can dramatically prevent secondary infections by medical staff that can occur when sampling high-risk respiratory viruses. It can solve many different problems such as fatigue and environmental problems.</p> <p>2. "Stem Cell Navigator"</p> <p>- Introduction: It is a medical device that can maximize the therapeutic effect of diseases by administering micro-sized structures including cell therapy products and capable of loading medicines in a minimally invasive manner, and moving them to target areas in the body using an electromagnetic external drive device.</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>[Patent]</p> <p>-registration in Korea : 3 -application in Korea : 9 -overseas application : 8</p> <p>[Thesis]</p> <p>- Characterization and Synthesis of Additive-coated BaTiO₃ Nano-powder and others -Human adipose-derived mesenchymal stem cell-based medical microrobot system for knee cartilage regeneration In vivo. (IF: 19.4) and 25 domestic and foreign films. -Liposomal angiogenic peptides for ischemic limb perfusion: comparative study between different administration methods. (IF: 6.4) and 27 domestic and foreign films.</p>

ClariPi Inc.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	ClariPi Inc.
○ Representative	Kim Jonghyo, Park Hyunsook
○ Establishment year	6 February, 2015
○ Specialized Field	Artificial Intelligence Medical Imaging Solution
○ Address	3F, 70-15, Ihwajang-gil, Jongno-gu, Seoul, 03088, Republic of KOREA
○ Home page	1. Homepage: http://www.claripi.com/
○ Enterprise Brief Introduction	<p>ClariPI provides innovative solutions to complex problems in the field of medical imaging by integrating big data with artificial intelligence image processing technologies.</p> <p>Our solutions provide imaging experts with clearer information and easy-to-use decision guidance for making confident diagnosis.</p>
○ Product and Pipeline Introduction	<p>1. ClariCT.AI is the company's artificial intelligence deep-learned technology that uses noise reduction technology. It is both FDA cleared and CE marked to offer a significant increase in CT image clarity, even with ultra-low-dose. It uses a deep convolutional neural network, trained to work in a vendor-agnostic way, to reduce noise and enhance image clarity for low-dose and ultra-low-dose DICOM CT images. Trained with over one million patient images containing varying degrees of noise for different body parts, its Clarity Engine separates image noise selectively while enhancing underlying structures; thus, providing clarity restored images.</p> <p>2. ClariPulmo is an AI-powered tri-functional solution kit best suited for low-dose lung CT screening. Our powerful pre-trained deep learning model provides accurate quantitative analysis of lung nodules as well as low-attenuation and high-attenuation lesions such as emphysema and pneumonia from low-dose CT images, despite strong image noise and varying scan conditions. The ClariPulmo in conjunction with the ClariCT.AI can help achieve the best practice in lung screening by reducing noise induced bias with this 3D reporting.</p> <p>3. ClariSigmam is an innovative breast cancer prediction marker. It is a breast density assessment solution that provides accurate and consistent density estimates from standard digital mammograms. Quantitative breast density is the main indicator in breast cancer screening and diagnosis. The powerful pre-trained deep learning model ensures to make consistent clinical decision marking in an objective and convenient way. Novel Deep Learning Technology provides a fully automated quantification for breast and mammary area and proportion density measurements. With the world's highest accuracy rate</p> <p>4. ClariAdipo is a system that helps to predict the risk of developing metabolic syndrome. It is a standalone S/W that analyzes DICOM CT abdomen fat image data sets.</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>1. Patent : 6 including APPARATUS AND METHOD FOR CT IMAGE DENOISING BASED ON DEEP (US10891762)</p> <p>2. Certification : GMP, ISO 13485</p> <p>3. License : FDA, CE, MFDS</p> <p>4. Thesis : 8 (Korea 2, Europe 6)</p> <ul style="list-style-type: none"> - Noise reduction approach in pediatric abdominal CT combining deep learning and dual-energy technique - Incremental Image Noise Reduction in Coronary CT Angiography Using a Deep Learning-Based Technique with Iterative Reconstruction - Application of Vendor-Neutral Iterative Reconstruction Technique to Pediatric Abdominal Computed Tomography - Effect of a novel denoising technique on image quality and diagnostic accuracy in low-dose CT in patients with suspected appendicitis - Impact of image denoising on image quality, quantitative parameters and sensitivity of ultra-low-dose volume perfusion CT imaging

Gaia agricultural corporation Ltd.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Gaia agricultural corporation Ltd.
○ Representative	Dong-hwan Kim
○ Establishment year	2011.05.16
○ Specialized Field	Health management field
○ Address	574-6, Seonbi-ro, Yeonsan-myeon, Nonsan-si, Chungna
○ Home page	- Homepage: www.itsnow.co.kr
○ Enterprise Brief Introduction	<p>Since salty taste is a food platform, it was judged that the Korean people could create a new genre for the first time if they could produce a “tasty salty taste” with little sodium, and researched and succeeded in technology development since 1998.(</p>
○ Product and Pipeline Introduction	<p>It is a food platform technology as a low-salt complex seasoning that can manufacture foods with salty taste and sodium content less than 50%.</p> <p>Rice, sugar, and salt are curses of 300, and are subject to intensive management in the country. Rice and sugar have substitutes, so you can control to some extent, but there is no substitute for salt (NaCl).</p> <p>ice, sugar, salt, three hundred curses referred to inde emphasis managed in the country’s rice and sugar substitutes one can be somewhat controlled salt (NaCl) is not an alternative government first salt less put and eat it singgeop (mateop) Second</p> <p>Third, it was said that the tongue was numbly hot and sweet so that the salty taste was not known, but this technology is a technology that replaces the salty taste with sweet, salty, bitter, sour, and umami by fermenting rice, soybeans, and anchovies.</p> <p>Third, hot, sweet, mepgo paralyzed tongue yeoteuna and knowing the technology salty rice, beans, and fermented anchovies, however, salty, bitter, sour, salty in flavor Im technology to replace</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>Patent registration 10-1336642,142359,1435530.1889933,2105455,210250, etc. including six cases. 10-1336642,142359,1435530.1889933,2105455,210250,</p> <p>Patent application 10-0114462 Japanese application 2020-215973 Japanese Patent Application 2020-215973 10-0114462</p> <p>Health New Technology Certification No.172.</p> <p>Fisheries traditional food certification (Marine Fisheries No. 174), HACCP certification</p>

GH Innotek Co., Ltd.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	GH Innotek Co., Ltd.
○ Representative	Gwon Yu Hong
○ Establishment year	2017(Year) 10(Month) 20(Day)
○ Specialized Field	Respiratory training devices and spirometer in the fields of medical and sports
○ Address	406-ho, 2, Busandaehak-ro 63beon-gil, Geumjeong-gu, Busan, Republic of Korea
○ Home page	- Homepage: http://www.ghit.co.kr/
○ Enterprise Brief Introduction	We manufacture and sell products related to respiration that rely on imports for localization in the medical and sports sectors.
○ Product and Pipeline Introduction	<ol style="list-style-type: none"> The world's first medical device capable of exercising in three modes → Inhalation, Exhalation, and Inhalation+Exhalation "All-in-One Respiratory Muscle Strengtheners IMT/PEP" - Introduction : This product is effective in improving respiratory function and rehabilitation such as increasing lung capacity, strengthening respiratory muscles, and getting rid of mucus from the lungs and airways. Controls inspiratory muscle contraction and relaxation "Inspiratory Muscle Trainer IMT" - Introduction : This product is effective in enhancing respiratory function such as increasing lung capacity, delaying lactate secretion, strengthening respiratory muscles, and increasing diaphragm thickness. The world's smallest size and pressure resistance type "Small Inspiratory Muscle Trainer S-IMT" - Introduction : This Product that has the same effect on smaller sized IMT The world's first "Vibration+Pressure resistance type Respiratory Muscle Strengtheners V-PEP/IMT" - Introduction : This product is effective in increasing lung capacity by getting rid of mucus from the lungs and airways through chest wall vibration and strengthening inspiratory muscles.
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Inspiratory Rehabilitation Device Patent ISO 13485, KFDA, FDA, PMDA Certification

Heimbiotek, Inc.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Heimbiotek, Inc.
○ Representative	Jae-Hoon Lee, Ph.D
○ Establishment year	2014
○ Specialized Field	R&D and Manufacturing of microRNA(miRNA) based molecular In Vitro Diagnostic Kits
○ Address	Pangyo Silicon Park A-201 35, Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
○ Home page	- Homepage: http://www.heimbiotek.com/
○ Enterprise Brief Introduction	Under the motto of “The Best or The First,” HeimBiotech secures the IP of gene detection and analysis and diagnosis technology with high technical and economic competitiveness through research and development of new gene detection and analysis mechanisms. Based on the secured IP, we develop and manufacture molecular diagnostic products.
○ Product and Pipeline Introduction	<p>1. HB miR Multi Assay Kit (RUO) RT-qPCR-based miRNA analysis kit developed with Heimbiotek original technology SBDE technology for high sensitivity, accuracy and reactivity.</p> <p>2. HB miRDx™ BKV Kit” CE IVD Multiplex Real-time RT-PCR kit which targets the miRNA biomarker bkv-miR-B1-5p in urine specimen from kidney transplant undergoing patient.</p> <p>3. HB BestPlex™ 3C COVID-19 RT-PCR Kit CE IVD Novel coronavirus diagnostic kit capable of determining false positives by positive controls with high sensitivity and specificity. The IVD kits capable of multiple detection with flu have also been developed and are in the final stages of clinical trials.</p> <p>miRNA based early diagnosis technology of liver cancer is under development, and HCMV infection-related immune recovery prediction technology is being developed.</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>1. Certification Corporate Research Institute Recognition (Korea Industrial Technology Association), GMP certification(Medical Device Manufacturing and Quality Management Standards, Clinical Use), ISO 13485(Medical Device Quality Management System), ISO 9001, Product CE-IVD / KFDA approval(for export) for BK virus and COVID-19 RT-PCR KIT, BRIC excellent product certification (17-E0322), and etc..</p> <p>2. Patent 10 patent application and 9 patent registrations which related to miRNA & molecular diagnostics such as miRNA detection technology, False-positive determining technology, and etc..</p> <p>3. Investment status Investment attraction : 3,500 (million Korean won)</p>

INNOYARD LTD.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	INNOYARD LTD.
○ Representative	Hsien Pin Chang, Huh Jin
○ Establishment year	2020
○ Specialized Field	3D sensing & image processing technology 3D printed device
○ Address	6-15, Dulle 3-gil, Seongdong-gu, Seoul, Korea
○ Home page	- Homepage: www.innoyard.net
○ Enterprise Brief Introduction	As a medical personnel, I always felt that the medical environment's efficiency leave a lot to be desired. After seeing no improvement in 5 years I decided to use technology to treat a particular disorder and expand from there.
○ Product and Pipeline Introduction	Cranio Orthosis Pipeline: Using mobile 3D scanners to scan the head of a baby to get a 3D model. The necessary computations are done on the 3D model to get various measurements of the head. The cranio orthosis is then created on top of the 3D model based on the measurement.
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Undergoing GMP phase 2 certification

INVITT.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	INVITT.
○ Representative	Kwangyun Yu
○ Establishment year	2021
○ Specialized Field	1. Wound Closure Device (Sutures, Tissue Adhesives, Staplers) 2. Endoscopic Vacuum Closure-assisted device
○ Address	Seoul
○ Home page	- Homepage:
○ Enterprise Brief Introduction	Established in 2021 with mission to realize domestic medical independence in Korea. Having experienced severely unstable supply of fundamental pharmaceuticals & medical devices during COVID, INVITT is willing to take part in propelling Korea's self-sufficiency in medical field. We have strong expertise in wound closure business which is a field with high dependence on imported brands, therefore we are working with local manufacturers to raise market presence of high-quality local products and technologies.
○ Product and Pipeline Introduction	1. Sutures, Tissue adhesives, Staplers - Products developed from local manufacturers 2. Endoscopic Vacuum Closure-assisted device - Minimally invasive method for the treatment of anastomotic leakage occurred in up to 15% of patients after lower&upper gastrointestinal resection - The treatment involves drainage mechanism to clean out infection, promote granulation leading to significant reduction of morbidity and mortality of patients
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	'Endoscopic Vacuum Closure-assisted device' is not yet commercialized in Korea but there is such high market demand which has led to making prototypes by users themselves and proved its efficacy in clinical studies. - JJ Hwang, YS Jeong, et al. Comparison of Endoscopic Vacuum Therapy and Endoscopic Stent Implantation With Self-Expandable Metal Stent in Treating Postsurgical Gastroesophageal Leakage. Medicine (Baltimore) 2016 Apr;95(16):e3416. - SH Kim, HS Choi, Endoscopic Vacuum Therapy for Esophageal Fistula), 2019.05. Korean Society of Gastrointestinal Endoscopy

Kukdong R&D Center(3D Materials)

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Kukdong R&D Center(3D Materials)
○ Representative	Nam YuRi
○ Establishment year	2013-02-01
○ Specialized Field	Biocompatible material (GelMA, PLA, PLGA, PCL, PLCL 등)
○ Address	Busan, Korea.
○ Home page	- Homepage: http://www.kd3dm.com/index2.php
○ Enterprise Brief Introduction	3D Materials is company that produces biocompatible material for bio 3D bioprinting. The Company is expanding its market with high-quality, low-priced strengths compared to other global competitor's bio-inks. We are constantly conducting research and development.
○ Product and Pipeline Introduction	1. Natural biodegradable polymer -GelMA(Gelatin Methacrylate) 2. Synthetic biodegradable polymer -PLA(Poly lactide), PCL(Polycaprolactone), -PLGA(Poly(lactide-co-glycolide)), -PLCL(Poly(lactide-co-caprolactone))
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	※Patent - Manufacturing method of water-soluble silk fibroin - Method for manufacturing silk fibroin structures for 3D printing - Bioink compositions for visible light curing for 3D printing and method of manufacturing the same

MCK Tech. Co., Ltd.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	MCK Tech. Co., Ltd.
○ Representative	Seungmin Cho
○ Establishment year	2017.02.20
○ Specialized Field	Graphene sensor-based electrolyte concentration detection system for home-care of ascites patients
○ Address	8-309, 156, Gajeongbuk-ro, Yuseong-gu, Daejeon, Republic of Korea
○ Home page	- Homepage: http://www.mcktech.co.kr
○ Enterprise Brief Introduction	<ul style="list-style-type: none"> - Established a company to develop sensor application technology that can create high added value by utilizing experience in developing graphene materials and parts. - Currently developing a sensor that detects the concentration of sodium ions in urine for home-care of ascites patients. And a joint research is underway to apply sensors to medical devices under development by a medical device company in Singapore. - Aiming to develop a system for home-care of ascites patients through mass production and clinical evaluation of the developed sensor.
○ Product and Pipeline Introduction	<ul style="list-style-type: none"> - In-body electrolyte monitoring system using graphene-based high-sensitivity ion detection sensor - Developed graphene-based Na⁺ ion detection sensor and performance evaluation completed. - Development of portable diagnostic device for home-care and performance evaluation in progress. - Expanding the line of sensors for measuring other electrolytes and detectables for disease diagnosis (K⁺, Cl⁻, creatinine sensors are being developed to improve diagnostic reliability).
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<ul style="list-style-type: none"> - 5 domestic and international patents for miniaturization and mass production of graphene sensors (3 domestic and 2 international) - Published 1 paper on graphene sensor - “Two-Dimensional Disposable Graphene Sensor to Detect Na⁺ Ions.” Nanomaterials 11.3 (2021): 787.) - Investment attraction contract on April 15, 2019 (40,050 thousand won)

Medihub Co., Ltd.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Medihub Co., Ltd.
○ Representative	HyunCheol Yeom
○ Establishment year	9 th of January, 2017
○ Specialized Field	Digital painless automatic syringe for dental Digital painless automatic syringe for medical purpose
○ Address	108, 175 LS-ro, Gunpo-si, Gyeonggi-do, South Korea
○ Home page	- Homepage: medihub.co.kr
○ Enterprise Brief Introduction	Established in 2017, we are passionately pursuing our business under the corporate slogan 'Leap to the global medical market beyond the domestic market' with the determination that we will pave the way for the development of the advanced country-type medical industry through the development of new technologies.
○ Product and Pipeline Introduction	1. Digital painless automatic syringe for dental, I-JECT Co-developed with Seoul National University Dental Hospital for 3 years. Minimize pain when administer anesthetic agent through PCGT 10 Second algorithm. 2. Digital hydraulic sinus lift kit, DSA Kit Using I-JECT' s accurate and steady injection, inject saline water for sinus lift without membrane rupture. 3. Lidocaine ampule and manual syringe temperature keeper and UV-C sterilizer, I-JECT ON. Keep temperature of lidocaine ampules and manual syringe for 30 Celsius degree. It helps to reduce inconvenience by temperature change to patient. Also UV-C sterilizer prevent cross infection of manual syringes and cartridges.
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	I-JECT : KGMP grade 2 Certification Patent : 6, ISO13485 Certification, GMP Certification Investment : total 987,000USD

NeoDex Corp.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	NoeDex
○ Representative	Soungjun Yoon
○ Establishment year	2019
○ Specialized Field	Dental equipment dental vision analysis
○ Address	C2-3, 112, Dogok-ro, Gangnam-gu, Seoul, Republic of Korea
○ Home page	- Homepage:
○ Enterprise Brief Introduction	<p>NeoDex CEO have dual majors. One is Material science and engineering, the other is Dentistry at Seoul national university. He is interested in fusion of engineering and dentistry.</p> <p>Business goal is after oral image recording, collection, AI Analysis of Oral image used to dental diagnosis, treatment, collaborative robot</p>
○ Product and Pipeline Introduction	equipment for soft tissue retraction and fluid suction without dental assist
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>Patent (dental treatment aids, patent application number 10-2020-0188676, request for examination)</p> <p>Developing product will obtain a license during may from food and drug administration</p> <p>Neodex was selected Initial start-up package program at 2020</p>

ORGAMEDI co.ltd

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	ORGAMEDI co.ltd
○ Representative	KWON DONG YEOB
○ Establishment year	2017
○ Specialized Field	Artificial blood Vessel & Biocompatible Material Product, Human organ model for organoid, Human Disease body model KWON DONG YEOB
○ Address	943,H-1 KIST Hwarangno 14gil 5 Seongbuk-gu,Seoul
○ Home page	- Homepage: http://www.orgamed.com/
○ Enterprise Brief Introduction	localization of artificial blood vessels that are 100% imported & Developing products for medical experiments instead of animal experiments
○ Product and Pipeline Introduction	Human disease model “Medibody” for surgical training using CT and MRI -Introduction: On January 17, 2020, a demonstration of the Department of Thoracic and Cardiovascular Surgery at Seoul National University Bundang Hospital proved to be an animal test and a surgical training superior to VR. Artificial blood vessels using new biocompatible materials -Introduction: Developing the world’s best functional artificial blood vessel by developing a new biocompatible material artificial blood vessel with 89% improvement in blood clot deposition
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Registered as a manufacturing company by the Public Procurement Service for human body model Patent registration: Heart model manufactured through 3D printer and its Manufacturing method

Remedia coporation

Category	Enterprise Creation																											
○ Corporation (Preliminary Enterprise)	Remedia coporation																											
○ Representative	yoonsungtae																											
○ Establishment year	2020 year																											
○ Specialized Field	Disposal eye sterile surgical set (for intravitreal injection)																											
○ Address	WIZBIZ 08, 14F, 361, World Cup buk-ro, Mapo-gu, Seoul, Republic of Korea																											
○ Home page	- Homepage:																											
○ Enterprise Brief Introduction	Remedia Co., Ltd. was established in June 2020 and is developing and selling the first disposable intravitreal injection sterilization treatment set in Korea. As such, we will strive to become a company that contributes to society through the medical industry.																											
○ Product and Pipeline Introduction	<div>- 1. Customized disposable intravitreal injection sterile surgical set</div> <div>*Disposal Eye Speculum</div> <div>- This product is a device that opens and fixes the eyelids to observe the eyeball during treatment or surgery (disposable)</div> <div>*Disposal Eye Caliper (medical gauge)</div> <div>- This product is a device used to measure the length of the human body during ophthalmic examinations and surgery. (Disposable)</div> <div>*Eye Surgery Set</div> <div>- This product is used to prevent contamination from the surrounding area by covering the area to be operated with surgical cloth, and it is a disposable medical device that does not have direct contact with the wound area or the inside of the human body.</div>																											
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<table><tr><td>2020</td><td>05</td><td>2 design patent applications</td></tr><tr><td></td><td>06</td><td>Established Remedia corporation</td></tr><tr><td></td><td>10</td><td>Designated as a member of health industry innovation start-up (Ministry of Health and Welfare)</td></tr><tr><td></td><td>11</td><td>Medical device manufacturing license</td></tr><tr><td></td><td>12</td><td>Medical device manufacturing report approval (eye injection set)</td></tr><tr><td></td><td>12</td><td>2 design patent applications and trademark application</td></tr><tr><td>2021</td><td>1</td><td>Designated as a venture business (technology guarantee)</td></tr><tr><td></td><td>1</td><td>Design patent registration (Disposal Eye Speculum)</td></tr><tr><td></td><td>3</td><td>Established a dedicated R&D department</td></tr></table>	2020	05	2 design patent applications		06	Established Remedia corporation		10	Designated as a member of health industry innovation start-up (Ministry of Health and Welfare)		11	Medical device manufacturing license		12	Medical device manufacturing report approval (eye injection set)		12	2 design patent applications and trademark application	2021	1	Designated as a venture business (technology guarantee)		1	Design patent registration (Disposal Eye Speculum)		3	Established a dedicated R&D department
2020	05	2 design patent applications																										
	06	Established Remedia corporation																										
	10	Designated as a member of health industry innovation start-up (Ministry of Health and Welfare)																										
	11	Medical device manufacturing license																										
	12	Medical device manufacturing report approval (eye injection set)																										
	12	2 design patent applications and trademark application																										
2021	1	Designated as a venture business (technology guarantee)																										
	1	Design patent registration (Disposal Eye Speculum)																										
	3	Established a dedicated R&D department																										

Shinwoo medison

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Shinwoo medison
○ Representative	Jeongkeun-KIM
○ Establishment year	June.2017
○ Specialized Field	<i>Medical Device Pressure-Free Needle Drug Injector</i>
○ Address	102-4dong, 42-10 Taejaggondan-gil, Wonju-si, Kangwon-Do
○ Home page	- Homepage: www.snmeison.com
○ Enterprise Brief Introduction	<p>Cost-effective medical devices become more competitive due to the price burden of imported medical devices and the development of domestic technologies</p> <p>Start a business with a vision to meet the needs of not only domestic but global markets based on the know-how and acuity of the painless drug injector.</p>
○ Product and Pipeline Introduction	<p>- - Air pressure-free injector: Drug delivery device in skin, obesity and pain areas by minimizing pain and relieving fear during needle injection using air pressure</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>KGMP TaiGMP 약물 주입기 특허 등록 2건</p>

TMD Lab Co., Ltd

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	TMD Lab Co., Ltd
○ Representative	Mi-Lan Kang
○ Establishment year	October 15, 2018
○ Specialized Field	Medical Devices for Insertion into the Human Body
○ Address	(HQ) 31, Gwangnaru-ro 8-gil, Seongdong-gu, Seoul, Republic of Korea
○ Home page	- Homepage: www.tmdlab.com
○ Enterprise Brief Introduction	TMD LAB is a corporate established to research and develop new material medical devices and cutting-edge biomedicine, with shape memory polymer and cell-derived nanovesicle base technology. In regard to shape memory polymer base technology, we have obtained the non-exclusive license from the industrial-educational cooperation group of Yonsei University along with the right to develop and make sales on a product with SMP. We also have secured the property right for the CNV base technology through patent application from TMD LAB itself. TMD LAB is on its way of preparing R&D and licensing on arthritis medicine based on CNV technology, and the human insertion stent with a new concept based on SMP base technology.
○ Product and Pipeline Introduction	<ol style="list-style-type: none"> 1. External Vascular Support: (1) Arteriovenous fistula surgery (Shunt surgery of connecting an artery and a vein near the skin, for a patient with chronic renal insufficiency under frequent hemodialysis treatments, so that the vein is expanded to have sufficient amount of blood flow, and is strengthened like the artery) 2. (2) Coronary artery bypass surgery (Surgery which creates a bypass for bloodstream) 3. provided to the heart, by connecting a duct (a radial artery near the wrist, or a saphenous vein in the leg), as an alternative to the narrow coronary artery) 4. Lacrimal duct stent (Maintaining the lacrimal duct diameter by self-expansion, after being inserted into the point of nasolacrimal duct obstruction) 5. Rhinoplasty Implant: Prevention of slipping and fixing effects, inhibition of biofilm formation, prevention of see-through.
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Series A round Investment (5.77 billion won) secured / Applied for 8 foreign journal papers, 6 domestic patents, and 2 PCTs / External Vascular support (designated as a newly developed medical device), Lacrimal stent (registration at MFDS in progress)

Well_C



Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Well_C
○ Representative	IN KYUNG PARK
○ Establishment year	2020.
○ Specialized Field	Laser Refractive Surgery(Ophthalmology)
○ Address	41-1Ro, Kang Seo Gu, Busan, Korea
○ Home page	- Homepage: wellc.kr
○ Enterprise Brief Introduction	In order to run the program service business, we developed laser software to correct corneal distortion. This software is produced to be mounted to vision correction laser.
○ Product and Pipeline Introduction	[vision up] - Cornea ablation planning software for corneal shape correction.
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>1. <u>Physiological Monitoring Device</u>. (GMP 2nd grade)</p> <p>2. Patent① Machine-Readable Medium, Keratotomy system, And keratotomy system) KR. EP 3275410, JP 6616839), US 10596039, ZL 201580077578.X)</p> <p>Patent②-LASER CORNEAL PHOTOABLATION METHOD AND SYSTEM FOR TREATING DRY EYE DISEASE(KR10-2021-0011416)</p> <p>3 SCI papers.</p> <p>① Laser asymmetric ablation method to improve corneal shape_ JoseAlberto Rodriguez Agudo 외.. Lasers In Medical Science. PO1-201911-21-005</p> <p>② Comparison between Surgical Outcomes of LASIK with and without Laser Asymmetric Keratectomy to Avoid Conventional Laser Refractive Surgery Adverse Effects _Scientific Reports.</p> <p>③ P01-202001-21-005. Comparison of Surgical Outcomes of Laser Refractive Surgery(LRS) Alone and LRS with Laser Asymmetric Keratectomy in Patients with Myopia_Medicine</p>

YBSOFT co., ltd.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	YBSOFT co., ltd.
○ Representative	Youngbae Yu
○ Establishment year	2013
○ Specialized Field	Fall Prevention wheelchair
○ Address	#902, C-dong, 158 Haneulmaeul-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10355, Korea
○ Home page	- Homepage: www.ybsoft.kr
○ Enterprise Brief Introduction	<ul style="list-style-type: none"> • Our Founder and CEO, Young Bae Yu, he got the idea to improve wheelchair safety after hearing about the problem of wheelchair accidents from the news. YBSOFT is founded in 2013 • Mission is to widely benefit the world by providing comfort satisfaction and happiness through our safety products. • In 2015 we came up with a unique idea for brake mechanism. • Estimated R&D and Factory • Over 60 patent and applications • approved NET (MOHW) • approved FDA
○ Product and Pipeline Introduction	<p>■ Fall prevention wheelchair(GOOD-LOCK)</p> <ol style="list-style-type: none"> 1. GL-010(Bar YBS) 2. GL-030(Hybrid YBS) 3. GL-350(2nd Bar YBS) <p>■ YB-Stroller</p> <p>■ Wheelchair for toddler</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>■ Patent</p> <ol style="list-style-type: none"> 1. Automatic Control Device For Foot Reset (Korea, no.102174705) 2. Wheelchair Brake System (US, no.15/526, 329) <p>■ FDA 510(K)</p>

Cosmetic

Benacell Co., Ltd.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Benacell Co., Ltd.
○ Representative	O.Y. Kang
○ Establishment year	June 24, 2019
○ Specialized Field	Research and development of antibacterial / anti-fungi materials and products that have excellent sustainability and effectiveness by applying nano fusion technology to natural mineral materials that are harmless to the human body.
○ Address	Room 324, 510, Misa-daero, Hanam-si, Gyeonggi-do, Republic of Korea
○ Home page	- Homepage: www.benacell.com
○ Enterprise Brief Introduction	Benacell produces antimicrobial label and PE/PP/PCR/TPU special resin (master batch) that can be applied to various products (film, cosmetics, clothing, shoes, kitchenware, health products, and medical devices) by developing antibacterial and anti-fungi materials.
○ Product and Pipeline Introduction	<p>1. Food freshness and anti-bacterial / anti-fungi label products 2. Special PE/PP resin (master batch) that can produce antimicrobial / anti-fungi films and plastic products 3. Special antibacterial / anti-fungi films and plastic products by order-based</p> <div style="display: flex; justify-content: space-around;">   </div>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>1. 21 patent applications: 10-2020-0026061, 0026063, 0026066, 0026067, 0026072, 0026075, 0027235~</p> <p>2. Additional patent applications in progress</p>

Medicosbiotech.Inc


Category	Enterprise Creation																	
○ Corporation (Preliminary Enterprise)	Medicobiotech.Inc																	
○ Representative	Won-Min, Yoo																	
○ Establishment year	2018																	
○ Specialized Field	1) New drug development Business 2) Biomaterial Business 3) Cosmeceutical Business																	
○ Address	201, 85-6, Jukdong-개 297beon-gil, Yoseong-gu, Daejeon, Republic of Korea																	
○ Home page	- Homepage: www.medicosbiotech.com																	
○ Enterprise Brief Introduction	Global leading company in bioindustry possessing the core personnel, technology, and the experience needed for new innovative drug development																	
○ Product and Pipeline Introduction	<table><tr><th>Product(Skill)</th><th>History</th><th>Market Plan</th></tr><tr><td>1) Spidrt Silk Protein</td><td>Development of scaffold, suture, bone regeneration treatment, etc using spider silk protein.</td><td>Possibility of developing a new medical equipment using biomaterial with special physical and biological properties</td></tr><tr><td>2) Cancer diagnosis kit</td><td>Verified sequence that is uniquely expressed in cancer cells</td><td>Cancer specific target may be used to be developed into a universal cancer diagnosis target and further as cancer vaccine</td></tr><tr><td>3) Cut wound medicine</td><td>Combination effective for skin regeneration may treat wounds from diabetic complications</td><td>Possibility to offer solutions for diabetic foot ulcer and radiation ulcer that have yet no clear treatments</td></tr><tr><td>4) Cosmeceutical</td><td>Sales of anti-alopecia hair care products for effective recovery of scalp</td><td>Effective scalp and skin care products that are growing world wide</td></tr></table>			Product(Skill)	History	Market Plan	1) Spidrt Silk Protein	Development of scaffold, suture, bone regeneration treatment, etc using spider silk protein.	Possibility of developing a new medical equipment using biomaterial with special physical and biological properties	2) Cancer diagnosis kit	Verified sequence that is uniquely expressed in cancer cells	Cancer specific target may be used to be developed into a universal cancer diagnosis target and further as cancer vaccine	3) Cut wound medicine	Combination effective for skin regeneration may treat wounds from diabetic complications	Possibility to offer solutions for diabetic foot ulcer and radiation ulcer that have yet no clear treatments	4) Cosmeceutical	Sales of anti-alopecia hair care products for effective recovery of scalp	Effective scalp and skin care products that are growing world wide
	Product(Skill)	History	Market Plan															
	1) Spidrt Silk Protein	Development of scaffold, suture, bone regeneration treatment, etc using spider silk protein.	Possibility of developing a new medical equipment using biomaterial with special physical and biological properties															
	2) Cancer diagnosis kit	Verified sequence that is uniquely expressed in cancer cells	Cancer specific target may be used to be developed into a universal cancer diagnosis target and further as cancer vaccine															
	3) Cut wound medicine	Combination effective for skin regeneration may treat wounds from diabetic complications	Possibility to offer solutions for diabetic foot ulcer and radiation ulcer that have yet no clear treatments															
4) Cosmeceutical	Sales of anti-alopecia hair care products for effective recovery of scalp	Effective scalp and skin care products that are growing world wide																
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	1) Patent - USA rnpA (15/533,273) - G-CGF (10-0716014) 2) Certification - USA FDA(80315-001.01) - JAPAN PMDA(13COX10651)																	

REACNF

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	REACNF (REd Algae Celluose Nano Fibril)
○ Representative	Jae-Hyun Han
○ Establishment year	2019.03.07
○ Specialized Field	Biofibers using algae, medical applications with nanocellulose, and cosmetic anti-aging materials
○ Address	- Head Office : #506, A dong, 197, Inje-ro, Gimhae-si, Gyeongsangnam-do, Republic of Korea - R&D Center: #805, Bldg 85, 20, Changwondaehak-ro, Uichang-gu, Changwon-si, Gyeongsangnam-do, Republic of KOREA
○ Home page	- Homepage: reacnf.com
○ Enterprise Brief Introduction	- Background: The importance of eco-friendly environment became the background of start-up in the forest resource department where I learned the foundation of management such as organization and goal management while serving as a student military education team. - Start-up: After conducting research and development in the field of natural environment, I started my own business through the Start-up Academy. - Currently: Commercialization, product implementation, and overseas export of marine algae bio-fibre development technology are underway. Currently, the company is focusing on developing marine algae anti-aging bio-nanocellulose materials that can be used for medical purposes and cosmetics. - Certification: Venture , research institute corporate
○ Product and Pipeline Introduction	1. Beauty mask sheet incorporating seaweed fiber 2. 4 types of beauty mask packs that incorporate seaweeds and extracts “Beauty curator” - Export to LA /USA, Hanoi/Vietnam and enter online and offline 3. Seaweed Nanocellulose/ Seaweed Carboxymethyl Pretreatment Nanocellulose - Development of medical materials in progress
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	1. Registered Patent: Bleaching Method for Manufacturing Process of Seaweed Pulp (No. 10-2223405) 2. Registred Patent: Manufacturing method of plate type particles through ball milling and calculation method of milling efficiency (No. 10-2076409) 3. Application: Manufacturing method of nanocellulose using algae(Application number 10-2021-0026458)

Health food products & IT

Dadak company

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Dadak company
○ Representative	Kim Yoohyun
○ Establishment year	2020.6.20
○ Specialized Field	Health Care Platform with personalized patient education contents
○ Address	Korea Biohealth Innovation & Start-up Center, Bongrae Bldg., 36, Chilpae-ro, Jung-gu, Seoul
○ Home page	- Homepage: https://dadakcompany.modoo.at/
○ Enterprise Brief Introduction	2020 Preliminary Startup Package (Korea Venture Business Womens Association) 2021 SBC Startup school(Gyeonggi Bukbu)
○ Product and Pipeline Introduction	<p>Health Care Platform for Obese patients that provides personalized patient education contents “Obesity Professional – Healthy together”</p> <ul style="list-style-type: none"> - by analyzing the risk of the obese patients the platform recommends doctor’s patient education contents that fix the health risk - the contents included in the platform is limited to long-term obesity management, which is difficult to find in usual search engines due to plastic surgery and beauty clinics.  <p>The image shows a screenshot of the Dadak company website on the left and a flowchart on the right. The website features a woman in a white lab coat and a red banner with the text '혼자서는 힘드니까! 비만주치의 같이건강' (It's hard to do alone! Let's be healthy with a doctor for obesity). The flowchart illustrates the service process: '비만환자' (Obese patient) leads to '문진표 작성 및 비만도 계산' (Writing medical history and calculating BMI), which leads to '강의영상 비만주치의' (Lecture video with doctor for obesity), and finally to '맞춤형 맞춤형 건강관리 콘텐츠' (Customized health management content). The content is categorized into '비만관리' (Obesity management) and '비만예방' (Obesity prevention), with specific topics like '비만관리' (Obesity management), '비만예방' (Obesity prevention), '비만관리' (Obesity management), and '비만예방' (Obesity prevention).</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	-

DELVER Incorporated

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	DELVER Incorporated
○ Representative	JAEJOON CHUNG
○ Establishment year	2020
○ Specialized Field	Specialized Electronic Quality Management System (EQMS) for Biopharmaceuticals
○ Address	Suite #409, Annex A, 12, Gaetbeol-ro, Yeonsu-gu, Incheon 21999, Republic of Korea
○ Home page	- Homepage: www.idelver.com
○ Enterprise Brief Introduction	<p>DELVER was established to provide the solutions in compliance with global regulations which enable to solve current CMC/Quality issues in Korea Biopharmaceutical industry.</p> <p>We have provided high quality consultation and well-established solution to our pilot clients. Upon our QMS document package product is developed on May, 2021, we will intensively focus on attracting customers. DELVER' s EQMS with high technology of Artificial Intelligence and Machine Learning will be completed within the first half of 2022 and be released to the domestic market before the end of 2022.</p>
○ Product and Pipeline Introduction	<p>1. Quality by Design (QbD)-driven QMS document package : Complete, lean, phase-appropriate and modernized Quality Management Systems which ensure quality consistency throughout overall product development life-cycle</p> <p>2. Artificial Intelligence · Machine Learning-driven EQMS “Antarctica AI™” : High-tech, Precise, Customized Quality Management Solution providing Big data Calculation and Analysis for Quality Risk Management and Quality Trend Analysis</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>Patent Application will be completed by May, 2021 for AI and Machine Learning-driven Quality Risk Management and Quality Trend Analysis Modules</p> <p>Patent Application will be completed by the end of 2021 for AI and Machine Learning-driven Experimental Designing Module</p>

SayM Co.,Ltd.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	SayM Co.,Ltd.
○ Representative	Choi,yong-hak
○ Establishment year	06/03/2011
○ Specialized Field	nerve-examination System
○ Address	58-1, Unjung-ro 225beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 1st floor
○ Home page	- Homepage: www.curelab.co.kr
○ Enterprise Brief Introduction	<p>Our company has a competitive advantage with the World' s only "Metachromatic Clothes method" nerve-examination System.</p> <ol style="list-style-type: none"> Scan the neurological abnormalities of the whole body at once (CT or MRI is unable to examine "pain and autonomic nerve disorders" Examination is possible on the back as well as the front of the body (The US Mayo Clinic method cannot simultaneously examine the back of the body) Able to determine the severity of the injury (Standard device for determining severity of the automobile accident)
○ Product and Pipeline Introduction	<p>"Bio-IT technology, a global leader in nervous system examination system "</p> <ol style="list-style-type: none"> 1μl/cm² accuracy Sweat calculation technology: Ultra-precise analysis of the sweat amount per unit area by using high optical technology Core body temperature heating technology: Scientific analysis of the rise in core temperature through wavelength World' s first metachromatic clothes technology: Creation of the new paradigm of the nervous system examination by introducing the world' s first metachromatic clothes manufacturing technology
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<ol style="list-style-type: none"> Acquired the certificate as an excellent company for Special Technology IPO (T-4) for two consecutive years patent No. 10-1479415 "Nerve examination system using skin perspiration reaction" (with Reagents) patent No. 10-2173387 "Advice which measures body parts' perspiration quantity using an alteration in brightness, and a method for measuring perspiration quantity" (Metachromatic clothing technology) Body temperature control sweat test new medical technology certification Certified by the Korea Research Institute of Standards and Science (S-CT clothes)

Whatvita co.,Ltd.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Whatvita co.,Ltd.
○ Representative	Bokki Kim
○ Establishment year	2017.12.15
○ Specialized Field	Mobile Digital Health Digital healthcare app service based on health functional food
○ Address	401,18,Jongam-ro,Seongbuk-gu,Seoul, Republic of Korea.
○ Home page	- Homepage: www.whatvita.kr
○ Enterprise Brief Introduction	Whatvita is a company that provides personalized healthcare services focused on prevention and management based on ICT. Currently, we recommend and develop customized health functional foods based on genetic tests, medication data, and life log data, and we are also developing a customized health management system in connection with them. We will improve the quality of life of our customers through these innovative and customized healthcare services.
○ Product and Pipeline Introduction	1. Whatvita Healthcare App - Health management service using dose check and contents 2. Whatvita Health Functional Food Recommendation Service - Whatvita recommends customized nutritional ingredients through genetics and healthcare data 3. Whatvita customized nutritional supplement ex) Banaba Ginkgo Leaf CoQ10-Blood sugar, blood pressure, blood circulation Green Tea Catechin, Omega 3-Cholesterol, Body Fat, Triglyceride
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<i>Patent</i> <i>1 Registration</i> <i>3 Application</i>